/**
 * Specialty market demand pages — GSC queries with meaningful impressions
 * outside page one. Content is qualitative intelligence anchored to real
 * regulators, tenders, and care pathways. No fabricated dollar totals.
 */

import { SPECIALTY_DEMAND_LONG_FORM, SPECIALTY_DEMAND_EXTRA_FAQS } from '@/data/specialtyMarketDemandLongForm';

export type SpecialtyMarketDemandContent = {
  slug: string;
  segmentLabel: string;
  badge: string;
  breadcrumbLabel: string;
  title: string;
  description: string;
  canonical: string;
  h1: string;
  intro: string[];
  hubLink?: { to: string; label: string };
  earlyLinks?: Array<{ to: string; label: string }>;
  dateModified?: string;
  researchTopics: Array<{ name: string; detail: string }>;
  demandDrivers: { heading: string; drivers: Array<{ title: string; detail: string }> };
  marketStructure: { heading: string; paragraphs: string[] };
  signalGrid?: { heading: string; items: Array<{ label: string; signal: string }> };
  calendarBlocks?: { heading: string; items: Array<{ period: string; detail: string }> };
  audiences: Array<{ audience: string; description: string }>;
  whyBionixus: string[];
  relatedLinks: Array<{ to: string; label: string }>;
  faqs: Array<{ question: string; answer: string }>;
  areaServed?: string[];
  priority: 'now' | 'next' | 'later';
  /** Direct answer block for search and LLM citation (visible SSR). */
  geoAnswer?: string;
  decisionBlueprint?: { why: string; evidence: string; next: string };
  proofMetrics?: Array<{ label: string; detail: string }>;
  deliveryPriorities?: string[];
  methodologyParagraphs?: string[];
  longFormSections?: Array<{ heading: string; paragraphs: string[] }>;
};

const BASE = 'https://www.bionixus.com';

const SHARED_WHY = [
  'Decision-led primary research — not syndicated table dumps',
  'Verified HCP, procurement, and access stakeholder recruitment',
  'Regulator- and pathway-aware study design from protocol one',
  'Comparable instruments for multi-country roll-ups when needed',
  'Board-ready synthesis with evidence gaps and owners flagged',
  '15+ years of healthcare research across 48 countries',
];

/* ------------------------------------------------------------------ */
/* NOW                                                                */
/* ------------------------------------------------------------------ */

const singaporeMedtechManufacturing: SpecialtyMarketDemandContent = {
  slug: 'singapore-medtech-manufacturing-market',
  segmentLabel: 'Singapore MedTech Manufacturing',
  badge: 'Singapore · MedTech Manufacturing',
  breadcrumbLabel: 'Singapore MedTech Manufacturing Market',
  title: 'Singapore MedTech Manufacturing Market Research | BioNixus',
  description:
    'Singapore MedTech manufacturing: who builds devices in Tuas and Woodlands, HSA manufacturing licences, CDMO capacity and ASEAN export routing. Primary research.',
  canonical: `${BASE}/singapore-medtech-manufacturing-market`,
  h1: 'Singapore MedTech Manufacturing Market: Research & Commercial Intelligence',
  intro: [
    'Singapore’s MedTech manufacturing market is not a retail-device story — it is an industrial and export story. Multinationals and Asian OEMs concentrate sterile assembly, implant finishing, diagnostics cartridge production, and contract manufacturing in Jurong, Tuas Biomedical Park, and allied industrial estates because HSA oversight, IP protection, and ASEAN/APAC logistics sit in one jurisdiction. BioNixus runs primary research that turns that manufacturing footprint into commercial decisions: capacity benchmarking, buyer qualification, partner selection, and expansion timing.',
    'Buyers searching “MedTech manufacturing Singapore” and “Singapore MedTech industry” need plant economics, regulatory manufacturing pathways, and hospital/OEM sourcing behaviour — not a generic MedTech market overview. Our programmes interview manufacturing directors, quality leads, procurement at export-focused OEMs, and hospital biomedical engineering teams that specify locally finished devices.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  earlyLinks: [
    { to: '/blog/medtech-singapore-2026-market-hsa-registration', label: 'medtech companies in Singapore guide' },
    { to: '/pharmaceutical-companies-singapore', label: 'pharmaceutical companies in Singapore directory' },
  ],
  dateModified: '2026-11-01',
  researchTopics: [
    {
      name: 'Manufacturing footprint & capacity mapping',
      detail:
        'Site-level intelligence on sterile fill-finish, assembly, packaging, and testing capacity across Singapore’s biomedical clusters — including CDMO versus captive OEM models.',
    },
    {
      name: 'HSA manufacturing & quality-system pathways',
      detail:
        'How HSA manufacturing licences, GDPMDS/GDP practices, and quality-system expectations shape time-to-produce and export-dossier readiness.',
    },
    {
      name: 'EDB / JTC investment and expansion signals',
      detail:
        'Incentive and cluster dynamics that change greenfield versus brownfield decisions for Asian and Western MedTech manufacturers.',
    },
    {
      name: 'OEM and hospital buyer qualification',
      detail:
        'What Asian hospital groups and global OEMs demand from Singapore-finished SKUs — documentation depth, dual-source rules, and lead-time reliability.',
    },
    {
      name: 'ASEAN / APAC export routing',
      detail:
        'How Singapore manufacturing is used as a regulatory and logistics springboard into ASEAN, Japan, Korea, Australia, and GCC tenders.',
    },
    {
      name: 'Workforce & cost-to-serve research',
      detail:
        'Talent, wage, and total-cost-to-serve trade-offs versus alternative APAC manufacturing bases — for internal investment committees.',
    },
  ],
  demandDrivers: {
    heading: 'What is driving Singapore MedTech manufacturing demand',
    drivers: [
      {
        title: 'China+1 and supply-risk diversification',
        detail:
          'OEMs and investors are rebalancing sterile and implant manufacturing toward trusted APAC jurisdictions with strong IP and export logistics.',
      },
      {
        title: 'ASEAN device demand growth',
        detail:
          'Hospital expansion across ASEAN raises demand for nearby manufactured SKUs with shorter lead times than EU or US plants.',
      },
      {
        title: 'Diagnostics and implant complexity',
        detail:
          'Cartridge IVD, active implants, and high-precision instruments favour Singapore’s quality and engineering depth.',
      },
      {
        title: 'Regulatory credibility for export',
        detail:
          'HSA-aligned manufacturing documentation supports leaner registration stories in ASEAN and reference-agency reliance pathways.',
      },
      {
        title: 'CDMO outsourcing wave',
        detail:
          'Mid-size MedTech firms prefer Singapore CDMO partners over building greenfield plants for early commercial volumes.',
      },
      {
        title: 'Hospital preference for reliable supply',
        detail:
          'Biomedical engineers and pharmacy buyers weight shortage history and documentation quality when specifying local finishers.',
      },
    ],
  },
  marketStructure: {
    heading: 'How the Singapore MedTech manufacturing market is structured',
    paragraphs: [
      'Which MedTech companies manufacture in Singapore? Global players with manufacturing, R&D, or regional-HQ presence include Medtronic, Johnson & Johnson, Becton Dickinson (BD), Boston Scientific, Baxter (Woodlands Industrial Park), Thermo Fisher Scientific, Siemens Healthineers, Stryker, and Beckman Coulter. The Singapore MedTech industry punches above its domestic market: the country produces roughly 60% of the world’s microarrays and one-third of its mass spectrometers, and medical devices and equipment manufacturing output was valued at about USD 12 billion in 2021.',
      'Singapore’s MedTech manufacturing base clusters around industrial biomedical estates with co-located test labs, sterile suppliers, and specialist logistics. Multinational captives sit alongside Asian OEM affiliates and independent CDMOs. Decision rights for capacity adds typically sit with regional manufacturing directors and global supply-chain committees — not Singapore sales teams alone.',
      'Commercial research must therefore separate three buyer contexts: (1) OEM partner selection for outsourced manufacture, (2) investment-committee diligence on plant expansion, and (3) hospital/public-procurement preference for Singapore-finished SKUs. BioNixus scopes modules to one of those decisions rather than mixing them into an undifferentiated “industry report.”',
      'For manufacturers also selling into Gulf tenders, Singapore manufacturing credentials often travel with the product story — SFDA and MOHAP buyers ask about origin of manufacture, quality system, and dual sources. We link Singapore manufacturing intelligence to GCC access work when that is on the critical path.',
    ],
  },
  signalGrid: {
    heading: 'Singapore manufacturing cluster signals',
    items: [
      {
        label: 'Tuas / Jurong biomedical estates',
        signal:
          'Primary concentration of sterile assembly, packaging, and warehouse-adjacent manufacturing with specialist subcontractor networks.',
      },
      {
        label: 'HSA manufacturing oversight',
        signal:
          'Licence and inspection cadence shapes how fast new lines can serve ASEAN and reference markets.',
      },
      {
        label: 'EDB-supported MedTech investments',
        signal:
          'Incentive and talent programmes keep high-value manufacturing competitive versus lower-cost ASEAN alternatives.',
      },
      {
        label: 'Hospital biomedical engineering buyers',
        signal:
          'Cluster hospitals influence which finished devices earn preferred listing when supply reliability is scored.',
      },
    ],
  },
  audiences: [
    {
      audience: 'Manufacturing & quality directors',
      description: 'Leaders choosing Singapore capacity, CDMO partners, or dual-source strategies.',
    },
    {
      audience: 'OEM and CDMO commercial teams',
      description: 'Firms selling manufacturing slots or finished-device supply into APAC programmes.',
    },
    {
      audience: 'Hospital biomedical engineering & procurement',
      description: 'Stakeholders who qualify Singapore-finished devices for cluster formularies and tenders.',
    },
    {
      audience: 'Investment & corporate development',
      description: 'Teams diligence plant expansions, JV structures, and China+1 manufacturing moves.',
    },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/blog/medtech-singapore-2026-market-hsa-registration', label: 'Medtech companies in Singapore and HSA registration' },
    { to: '/pharmaceutical-companies-singapore', label: 'Pharmaceutical companies in Singapore' },
    { to: '/singapore-medtech-market-research', label: 'MedTech market research in Singapore' },
    { to: '/singapore-medical-devices-market-report', label: 'Singapore medical devices market report' },
    { to: '/pharmaceutical-market-research-singapore', label: 'Pharmaceutical market research Singapore' },
    { to: '/healthcare-market-research-singapore', label: 'Healthcare market research Singapore' },
    { to: '/japan-medical-devices-market-report', label: 'Japan medical devices market report' },
    { to: '/clinical-diagnostics-market-research', label: 'Clinical diagnostics market research' },
  ],
  faqs: [
    {
      question: 'What is the Singapore MedTech manufacturing market?',
      answer:
        'It is the ecosystem of captive OEM plants, CDMOs, and supply-chain partners producing or finishing medical devices and diagnostics in Singapore for domestic use and APAC/ASEAN export — governed by HSA manufacturing rules and clustered in biomedical industrial estates.',
    },
    {
      question: 'Which MedTech companies manufacture in Singapore?',
      answer:
        'Medtronic, Johnson & Johnson, BD, Boston Scientific, Baxter, and Thermo Fisher Scientific run device manufacturing in Singapore, while Siemens Healthineers, Stryker, and Beckman Coulter run regional operations. Baxter’s plant is at Woodlands Industrial Park; pharma and biologics plants concentrate at Tuas Biomedical Park.',
    },
    {
      question: 'Why do MedTech firms manufacture in Singapore?',
      answer:
        'Firms cite IP protection, HSA regulatory credibility, specialist talent, ASEAN logistics, and China+1 diversification. BioNixus validates those claims with plant and buyer interviews rather than brochure narratives.',
    },
    {
      question: 'How does BioNixus research Singapore MedTech manufacturing?',
      answer:
        'We run primary interviews and surveys with manufacturing, quality, OEM commercial, and hospital procurement stakeholders, then map findings to a single investment, partner-selection, or tender decision.',
    },
    {
      question: 'Can Singapore manufacturing research link to GCC tenders?',
      answer:
        'Yes. Origin-of-manufacture and quality-system evidence often travels into SFDA and MOHAP tender dossiers; BioNixus connects Singapore manufacturing modules to GCC market-access research when needed.',
    },
  ],
  areaServed: ['Singapore'],
  priority: 'now',
};

const singaporePharmaceuticalMarket: SpecialtyMarketDemandContent = {
  slug: 'singapore-pharmaceutical-market',
  segmentLabel: 'Singapore Pharmaceutical Market',
  badge: 'Singapore · Pharmaceuticals',
  breadcrumbLabel: 'Singapore Pharmaceutical Market',
  title: 'Singapore Pharmaceutical Market Intelligence 2026 | BioNixus',
  description:
    'Singapore pharmaceutical market intelligence — HSA registration, ACE HTA, MOH SDL/MAF subsidy listing, SingHealth/NUHS/NHG cluster dynamics, and APAC hub.',
  canonical: `${BASE}/singapore-pharmaceutical-market`,
  h1: 'Singapore Pharmaceutical Market: Structure, Access & Commercial Intelligence',
  intro: [
    'The Singapore pharmaceutical market is small by population but outsized as an APAC headquarters, regulatory, and access proving ground. HSA registration opens the door; ACE appraisal and MOH Standard Drug List / Medication Assistance Fund decisions determine whether products are affordable in public care. BioNixus delivers market intelligence that separates hub optics from real cluster uptake — so commercial teams do not mistake Singapore HQ presence for market share.',
    'Search for “Singapore pharma market” usually signals sizing, access sequencing, and competitor mapping needs. Our programmes combine desk structure with primary physician, pharmacy, and access interviews across SingHealth, NUHS, and NHG — then link findings to ASEAN or GCC expansion where that is the real P&L question.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    {
      name: 'Market structure & channel mix',
      detail:
        'Public cluster versus private specialty share, hospital-administered versus retail pathways, and where volume actually concentrates by therapy area.',
    },
    {
      name: 'HSA → ACE → MOH subsidy pathway',
      detail:
        'Evidence and timing map from registration through ACE cost-effectiveness to SDL/MAF listing decisions that unlock public uptake.',
    },
    {
      name: 'Cluster formulary behaviour',
      detail:
        'How SingHealth, NUHS, and NHG evaluate oncology, immunology, and chronic-care brands beyond national subsidy lists.',
    },
    {
      name: 'APAC hub commercial intelligence',
      detail:
        'Separating Singapore HQ and medical-affairs footprint from in-market prescribing and tender wins.',
    },
    {
      name: 'Competitor and analogue mapping',
      detail:
        'Brand, biosimilar, and therapeutic-class analogues with access and message implications.',
    },
    {
      name: 'ASEAN / GCC sequencing briefs',
      detail:
        'When Singapore evidence travels usefully to Malaysia, Indonesia, or Gulf access dossiers — and when it does not.',
    },
  ],
  demandDrivers: {
    heading: 'Forces shaping the Singapore pharmaceutical market',
    drivers: [
      {
        title: 'Subsidy-gated public uptake',
        detail:
          'SDL/MAF and financing schemes (MediShield Life, MediSave, CHAS) dominate affordability in public pathways.',
      },
      {
        title: 'ACE health-technology assessment',
        detail:
          'Cost-effectiveness expectations set the evidence bar before national funding conversations advance.',
      },
      {
        title: 'Cluster hospital concentration',
        detail:
          'High specialty volumes concentrate in a small set of public institutions — account strategy matters.',
      },
      {
        title: 'APAC headquarters density',
        detail:
          'Regional medical and commercial roles inflate presence indicators unless primary research corrects them.',
      },
      {
        title: 'Oncology and specialty growth',
        detail:
          'High-cost classes drive most strategic briefs BioNixus fields from multinational sponsors.',
      },
      {
        title: 'Reference-market spillover',
        detail:
          'Singapore access narratives are reused in ASEAN and sometimes GCC strategy debates — correctly or not.',
      },
    ],
  },
  marketStructure: {
    heading: 'How the Singapore pharmaceutical market works in practice',
    paragraphs: [
      'Public clusters dominate specialty care; private specialists and retail pharmacies matter more in primary and elective categories. Registration without subsidy listing often strand brands in a narrow cash-pay or private channel. BioNixus therefore treats ACE and MOH subsidy context as commercial structure — not regulatory trivia.',
      'Because Singapore is frequently the first Asian dossier or APAC medical hub, global teams ask for “market size” answers that should really be framed as access-gated uptake scenarios. We deliver scenario structure with primary validation rather than a single invented total.',
    ],
  },
  signalGrid: {
    heading: 'Access and care-delivery signals',
    items: [
      {
        label: 'HSA registration',
        signal: 'Necessary but rarely sufficient for public-volume commercial success.',
      },
      {
        label: 'ACE appraisal',
        signal: 'Evidence and economic narrative gate that shapes MOH funding conversations.',
      },
      {
        label: 'SDL / MAF listing',
        signal: 'Main public affordability switch for many chronic and specialty products.',
      },
      {
        label: 'Cluster formularies',
        signal: 'SingHealth, NUHS, and NHG still impose product-level and protocol filters.',
      },
    ],
  },
  audiences: [
    {
      audience: 'Specialist physicians & KOLs',
      description: 'Oncology, immunology, cardiometabolic, and rare-disease leaders driving protocol choice.',
    },
    {
      audience: 'Hospital pharmacy & formulary committees',
      description: 'Cluster stakeholders who convert national listing into ward and clinic use.',
    },
    {
      audience: 'Access / HEOR & medical affairs',
      description: 'Teams building ACE and subsidy dossiers and payer narratives.',
    },
    {
      audience: 'APAC commercial leadership',
      description: 'Regional leads sequencing Singapore versus ASEAN and GCC investments.',
    },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/pharmaceutical-market-research-singapore', label: 'Pharmaceutical market research Singapore' },
    { to: '/healthcare-market-research-singapore', label: 'Healthcare market research Singapore' },
    { to: '/singapore-medtech-manufacturing-market', label: 'Singapore MedTech manufacturing market' },
    { to: '/singapore-medical-devices-market-report', label: 'Singapore medical devices market report' },
    { to: '/pharmaceutical-market-research-japan', label: 'Pharmaceutical market research Japan' },
    { to: '/healthcare-market-research', label: 'Healthcare market research hub' },
  ],
  faqs: [
    {
      question: 'How large is the Singapore pharmaceutical market?',
      answer:
        'Singapore’s pharmaceutical market is moderated by population size but concentrated in high-value specialty care and public-subsidy pathways. BioNixus sizes categories from access-gated uptake and primary stakeholder research rather than publishing a single unaudited national total as fact.',
    },
    {
      question: 'What determines real access in Singapore?',
      answer:
        'HSA registration, ACE appraisal, MOH SDL/MAF subsidy decisions, financing scheme design, and cluster formulary behaviour all matter. Research should map that sequence for each brand, not stop at registration.',
    },
    {
      question: 'How is this page different from BioNixus pharmaceutical market research Singapore?',
      answer:
        'This page is market-structure and access intelligence for the “Singapore pharmaceutical market” query. /pharmaceutical-market-research-singapore is the BOFU service page for commissioning Singapore fieldwork programmes.',
    },
  ],
  areaServed: ['Singapore'],
  priority: 'now',
};

const japanGeneralSurgicalDevices: SpecialtyMarketDemandContent = {
  slug: 'japan-general-surgical-devices-market',
  segmentLabel: 'Japan General Surgical Devices',
  badge: 'Japan · Surgical Devices',
  breadcrumbLabel: 'Japan General Surgical Devices Market',
  title: 'Japan General Surgical Devices Market Research | BioNixus',
  description:
    'Japan general surgical devices market intelligence — OR procurement, PMDA pathways, NHI functional classification, laparoscopy and energy devices, and.',
  canonical: `${BASE}/japan-general-surgical-devices-market`,
  h1: 'Japan General Surgical Devices Market: Research & Commercial Intelligence',
  intro: [
    'Japan’s general surgical devices market sits inside the world’s third-largest medical device economy — with OR adoption shaped by PMDA classification, NHI functional category pricing, and hospital capital planning rather than US-style IDN contracts alone. BioNixus researches stapler, energy, laparoscopy, clip, and open-surgery instrument decisions with surgeons, OR nurses, and hospital procurement so launch teams know which accounts move volume.',
    'Generic “Japan medical devices” reports bury general surgery inside imaging and endoscopy giants. This page isolates the surgical-instruments and OR consumables decision set so OEMs can brief Japan without competing for attention against MRI and endoscopy headlines.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    {
      name: 'OR adoption & technique migration',
      detail:
        'Laparoscopic versus open vs robotic-adjacent instrument use, and what changes stapling, energy, and clip preference.',
    },
    {
      name: 'Hospital procurement & capital cycles',
      detail:
        'How Japanese hospitals score price, service contracts, training burden, and total cost of ownership for general surgery SKUs.',
    },
    {
      name: 'PMDA class & predicate strategy',
      detail:
        'Classification and clinical-evidence expectations that shape Japan entry timing for new surgical platforms.',
    },
    {
      name: 'NHI category pricing implications',
      detail:
        'Functional classification effects on reusable versus disposable strategy and premium claims.',
    },
    {
      name: 'Competitive objection libraries',
      detail:
        'Surgeon and nurse switch barriers across Olympus-adjacent workflows and multinational stapling/energy portfolios.',
    },
    {
      name: 'Training & KOL cascade mapping',
      detail:
        'Which university hospitals and high-volume community ORs actually set technique norms regionally.',
    },
  ],
  demandDrivers: {
    heading: 'Demand drivers in Japan general surgical devices',
    drivers: [
      {
        title: 'Aging surgical volumes',
        detail: 'Older-patient procedure mix lifts demand for efficient, low-complication general surgery workflows.',
      },
      {
        title: 'Minimally invasive migration',
        detail: 'Ongoing laparoscopy and energy-device substitution reframes stapler and instrument baskets.',
      },
      {
        title: 'Device-lag reduction',
        detail: 'Faster PMDA pathways make concurrent Japan launches more realistic for innovative platforms.',
      },
      {
        title: 'Hospital cost pressure',
        detail: 'Procurement committees intensify TCO and service-contract scrutiny on OR consumables.',
      },
      {
        title: 'Domestic OEM strength',
        detail: 'Japanese manufacturers remain influential referents in surgeon preference research.',
      },
      {
        title: 'Training bottleneck',
        detail: 'OR nurse and surgeon training bandwidth gates how fast new platforms spread beyond KOLs.',
      },
    ],
  },
  marketStructure: {
    heading: 'Market structure for general surgical devices in Japan',
    paragraphs: [
      'Japan’s hospital density and NHI coverage create high baseline procedure volume, but SKU choice concentrates in university and high-volume community hospitals first. Distributors and manufacturer clinical specialists jointly shape OR familiarity; service and training often decide switches as much as stapling performance claims.',
      'BioNixus designs Japan general surgery programmes around a single decision — launch sequencing, competitive defence, or portfolio rationalisation — then recruits surgeons, OR nurses, biomedical engineers, and procurement with verified practice settings.',
    ],
  },
  signalGrid: {
    heading: 'Category signals',
    items: [
      { label: 'Energy & advanced dissection', signal: 'Technique migration hotspot with training-heavy adoption curves.' },
      { label: 'Stapling & clip systems', signal: 'High volume; loyalty tied to OR familiarity and complication risk.' },
      { label: 'Laparoscopic instruments', signal: 'Capex plus disposable mix; committee TCO scrutiny rising.' },
      { label: 'Open surgery instrumentation', signal: 'Still material in community hospitals and selected case types.' },
    ],
  },
  audiences: [
    { audience: 'General & MIS surgeons', description: 'Procedure owners who decide platform familiarity and brand loyalty.' },
    { audience: 'OR nursing leads', description: 'Workflow and setup stakeholders who make or break adoption.' },
    { audience: 'Hospital procurement / VAS', description: 'Committees scoring price, service, and standardization.' },
    { audience: 'Biomedical engineering', description: 'Maintenance, capital, and inventory gatekeepers.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/japan-medical-devices-market-report', label: 'Japan medical devices market report' },
    { to: '/pharmaceutical-market-research-japan', label: 'Pharmaceutical market research Japan' },
    { to: '/healthcare-market-research-japan', label: 'Healthcare market research Japan' },
    { to: '/singapore-medtech-manufacturing-market', label: 'Singapore MedTech manufacturing market' },
    { to: '/gcc-anesthesia-surgical-market-report', label: 'GCC anesthesia & surgical market report' },
  ],
  faqs: [
    {
      question: 'What is included in the Japan general surgical devices market?',
      answer:
        'Typically staplers, energy devices, clips, laparoscopic instruments, and related OR consumables/capital — excluding bulk imaging and endoscopy capital systems that dominate broader “medical devices” headlines.',
    },
    {
      question: 'How does NHI affect surgical device choice in Japan?',
      answer:
        'Devices map into functional reimbursement categories; premiums for genuine innovation require clear clinical differentiation. BioNixus researches how those category dynamics influence hospital standardization decisions.',
    },
    {
      question: 'Does BioNixus recruit Japanese surgeons for device research?',
      answer:
        'Yes — verified surgeons, OR nurses, and procurement stakeholders, with instruments designed for Japanese hospital workflow and reporting suitable for global portfolio committees.',
    },
  ],
  areaServed: ['Japan'],
  priority: 'now',
};

const healthcareBioconvergence: SpecialtyMarketDemandContent = {
  slug: 'healthcare-bioconvergence-market',
  segmentLabel: 'Healthcare Bioconvergence',
  badge: 'Global · Bioconvergence',
  breadcrumbLabel: 'Healthcare Bioconvergence Market',
  title: 'Healthcare Bioconvergence Market Research | BioNixus',
  description:
    'Healthcare bioconvergence market research — where biotech, MedTech, digital health, and materials science converge. Stakeholder mapping, partnership.',
  canonical: `${BASE}/healthcare-bioconvergence-market`,
  h1: 'Healthcare Bioconvergence Market: Research for Converging Life-Science Platforms',
  intro: [
    'Healthcare bioconvergence is the commercial meeting point of biology, engineering, computing, and materials — from bioelectronic medicine and tissue engineering to AI-enabled diagnostics and cell-device combination platforms. Buyers searching this term need partnership maps, evidence pathways, and buyer readiness — not a glossary essay. BioNixus runs primary research with clinicians, hospital innovation offices, regulators’ adjacent advisors, and corporate BD teams to test where bioconvergence products actually clear hospital and access gates.',
    'Because the category straddles drugs, devices, and software, generic MedTech or pharma reports miss the decision rights. Our programmes frame one decision first — partner selection, indication prioritisation, or hospital adoption — then recruit the stakeholders who hold that decision.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    {
      name: 'Hospital innovation & adoption research',
      detail:
        'How academic medical centres and private hospital groups evaluate bioconvergence pilots versus standard of care.',
    },
    {
      name: 'Partnership and BD diligence interviews',
      detail:
        'What pharma, MedTech, and tech buyers require before term sheets for platform or asset partnerships.',
    },
    {
      name: 'Regulatory pathway mapping',
      detail:
        'Drug-device, SaMD, and combination-product evidence expectations across US, EU, GCC, and APAC reference markets.',
    },
    {
      name: 'Clinician workflow readiness',
      detail:
        'Training, infra, and care-pathway friction that stalls deployments after technical proof-of-concept.',
    },
    {
      name: 'Payer and value narrative tests',
      detail:
        'Whether health systems and payers treat bioconvergence offerings as devices, procedures, or high-cost therapies.',
    },
    {
      name: 'Cluster / ecosystem benchmarking',
      detail:
        'Competitive positioning across Singapore, Israel, Boston, and Gulf innovation hubs for corporate investment committees.',
    },
  ],
  demandDrivers: {
    heading: 'Why bioconvergence is on commercial agendas now',
    drivers: [
      {
        title: 'Platform valuation pressure',
        detail: 'Investors demand hospital and partnership evidence earlier in asset timelines.',
      },
      {
        title: 'Hospital digital & device fusion',
        detail: 'OR, ICU, and diagnostics workflows now assume software-plus-biology stacks.',
      },
      {
        title: 'Combination-product pipelines',
        detail: 'More assets require dual drug-device regulatory and access stories.',
      },
      {
        title: 'Asia hub competition',
        detail: 'Singapore and other APAC hubs compete for manufacturing and clinical partners.',
      },
      {
        title: 'Gulf innovation tenders',
        detail: 'Vision 2030-era health megaprojects create early-adopter hospital opportunities.',
      },
      {
        title: 'AI diagnostics regulation',
        detail: 'Clearer SaMD rules make commercial timelines more plannable — and diligence more rigorous.',
      },
    ],
  },
  marketStructure: {
    heading: 'How to research a bioconvergence market without false precision',
    paragraphs: [
      'Bioconvergence is a lens, not a single SKU class. Credible research segments by use case — regenerative implants, bioelectronics, AI pathology, cell-device delivery — then maps buyers accordingly. BioNixus does not invent a global dollar total for “the bioconvergence market”; we size addressable decision cells with primary validation.',
      'Corporate teams typically need three deliverables: (1) a stakeholder map with decision rights, (2) evidence-gap and pathway implications, and (3) a partner shortlist with interview-backed fit criteria. That is the shape of our standard briefing.',
    ],
  },
  audiences: [
    {
      audience: 'Hospital innovation & clinical champions',
      description: 'Stakeholders who pilot or block new platforms inside health systems.',
    },
    {
      audience: 'Pharma / MedTech BD and strategy',
      description: 'Teams diligence-ing partnerships, options, and geographic bets.',
    },
    {
      audience: 'Regulators-adjacent advisors & KOLs',
      description: 'Experts who shape evidence expectations for combination and SaMD pathways.',
    },
    {
      audience: 'Investors & corporate development',
      description: 'Capital allocators needing primary market reality checks.',
    },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/singapore-medtech-manufacturing-market', label: 'Singapore MedTech manufacturing market' },
    { to: '/clinical-diagnostics-market-research', label: 'Clinical diagnostics market research' },
    { to: '/real-world-evidence', label: 'Real world evidence' },
    { to: '/healthcare-market-research', label: 'Healthcare market research hub' },
    { to: '/bionixus-industries', label: 'BioNixus industries hub' },
    { to: '/japan-medical-devices-market-report', label: 'Japan medical devices market report' },
  ],
  faqs: [
    {
      question: 'What is healthcare bioconvergence?',
      answer:
        'It is the commercial and R&D convergence of biology with engineering, computing, and materials — spanning bioelectronics, regenerative platforms, AI diagnostics, and combination products that sit between classic pharma and MedTech categories.',
    },
    {
      question: 'How large is the healthcare bioconvergence market?',
      answer:
        'Published “global totals” often mix incompatible asset classes. BioNixus scopes addressable opportunity by use case and buyer pathway with primary research rather than quoting a single unverifiable headline.',
    },
    {
      question: 'Who buys bioconvergence products?',
      answer:
        'Depending on the asset: hospital innovation offices, specialty clinical departments, payers via procedure or high-cost therapy pathways, and corporate BD partners — rarely a single procurement lane.',
    },
  ],
  priority: 'now',
};

const nupcoTenderCalendar: SpecialtyMarketDemandContent = {
  slug: 'nupco-tender-calendar-events-2026',
  segmentLabel: 'NUPCO Tender Calendar 2026',
  badge: 'Saudi Arabia · NUPCO',
  breadcrumbLabel: 'NUPCO Tender Calendar & Events 2026',
  title: 'NUPCO Tender Calendar & Events 2026 | BioNixus',
  description:
    'NUPCO tender calendar and events planning for 2026 — framework-agreement cycles, conference timing, hospital pull-through signals, and primary research.',
  canonical: `${BASE}/nupco-tender-calendar-events-2026`,
  h1: 'NUPCO Tender Calendar & Events 2026: Planning Intelligence for Saudi Access Teams',
  intro: [
    'NUPCO remains the Kingdom’s central procurement spine for MOH and a widening set of public facilities. Teams searching “NUPCO tender conference” or “NUPCO event 2026” usually need timing discipline — when framework agreements refresh, when supplier events concentrate, and when hospital pull-through research should land — not a PDF of every lot number. BioNixus publishes planning intelligence that connects the tender calendar to commercial fieldwork.',
    'Use this page with our deeper NUPCO tendering guide for process mechanics, then commission primary research for molecule- or category-specific award strategy. Calendar statements should always be revalidated against NUPCO’s live notices before bid decisions.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    {
      name: 'Framework-agreement cycle tracking',
      detail:
        'Therapeutic-area framework timing, pre-qualification windows, and when hospital demand pull materialises after listing.',
    },
    {
      name: 'Event & conference calendar mapping',
      detail:
        'Supplier forums, sector conferences, and Saudi access events where NUPCO-facing conversations concentrate in 2026.',
    },
    {
      name: 'Category readiness assessments',
      detail:
        'Whether your SKU’s ICV, supply, and clinical-evidence story is ready before the next relevant framework window.',
    },
    {
      name: 'Hospital pull-through research',
      detail:
        'Post-award interviews that explain why listed products convert — or stall — inside MOH and affiliated hospitals.',
    },
    {
      name: 'Competitor award surveillance',
      detail:
        'Win/loss themes and messaging patterns from recent analogous awards for commercial war-rooms.',
    },
    {
      name: 'ICV & localization diligence',
      detail:
        'How In-Country Value expectations are scoring in live categories your team intends to chase.',
    },
  ],
  demandDrivers: {
    heading: 'Why calendar discipline matters for NUPCO categories',
    drivers: [
      {
        title: 'Framework shift since 2024',
        detail: 'Demand-driven frameworks changed volume timing versus legacy fixed-quantity awards.',
      },
      {
        title: 'Vision 2030 localization',
        detail: 'ICV scoring makes readiness windows more decisive than price alone.',
      },
      {
        title: 'Event-driven networking',
        detail: 'Supplier and hospital forums still cluster key relationship cycles into calendar peaks.',
      },
      {
        title: 'Category clustering',
        detail: 'Oncology, biosimilars, and high-volume injectables move on distinct framework cadences.',
      },
      {
        title: 'Evidence requirements rising',
        detail: 'Budget-impact and clinical-confidence docs need runway before portals open.',
      },
      {
        title: 'Affiliate bandwidth',
        detail: 'Global teams miss Saudi windows without a shared planning calendar.',
      },
    ],
  },
  marketStructure: {
    heading: 'How to use a NUPCO calendar without treating it as legal advice',
    paragraphs: [
      'Official tender notices, e-procurement portals, and NUPCO communications remain authoritative. This page is commercial planning intelligence — BioNixus translates typical seasonal patterns, category clustering, and event timing into research calendars for access and business-development teams.',
      'For process depth — bidder registration, document packs, and award mechanics — start with the NUPCO Saudi Arabia tendering guide, then return here for 2026 planning checkpoints and research module timing.',
    ],
  },
  calendarBlocks: {
    heading: '2026 NUPCO planning checkpoints (indicative)',
    items: [
      {
        period: 'Q1 2026 — readiness & pre-qualification',
        detail:
          'Confirm documentation packs, ICV narratives, and sample hospital references before major framework refreshes. Commission win/loss interviews on prior analogous awards.',
      },
      {
        period: 'Q2 2026 — framework & supplier-forum season',
        detail:
          'Peak period for many therapeutic-area conversations and industry events. Run live competitive-message testing with pharmacy and procurement while windows are open.',
      },
      {
        period: 'Q3 2026 — hospital pull-through',
        detail:
          'Measure whether framework placement converts to ward and formulary use. Identify bottlenecks in distribution, clinician confidence, or substitution rules.',
      },
      {
        period: 'Q4 2026 — portfolio & 2027 sequencing',
        detail:
          'Re-forecast volumes and lock 2027 evidence and localization investments against expected framework cycles.',
      },
    ],
  },
  audiences: [
    {
      audience: 'Market access & tender leads',
      description: 'Owners of NUPCO strategy, documentation, and award reviews.',
    },
    {
      audience: 'Hospital pharmacy stakeholders',
      description: 'Influencers of post-award substitution and consumption.',
    },
    {
      audience: 'Local partners & distributors',
      description: 'Execution partners who need shared calendar and evidence packs.',
    },
    {
      audience: 'Global affiliate commercial teams',
      description: 'Regional leads aligning Saudi windows with global launch calendars.',
    },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/blog/nupco-saudi-arabia-tendering-guide', label: 'NUPCO Saudi Arabia tendering guide' },
    { to: '/gcc-market-access-guide', label: 'GCC pharmaceutical market access guide' },
    { to: '/sfda-market-access-strategy-saudi-arabia', label: 'SFDA market access strategy Saudi Arabia' },
    { to: '/healthcare-market-research/saudi-arabia', label: 'Healthcare market research Saudi Arabia' },
    { to: '/gcc-generic-injectables-market', label: 'GCC generic injectables market' },
    { to: '/market-research-saudi-arabia-pharmaceutical', label: 'Market research Saudi Arabia pharmaceutical' },
  ],
  faqs: [
    {
      question: 'Where can I find the official NUPCO tender calendar for 2026?',
      answer:
        'Always rely on NUPCO’s official portals and notices for lot-level dates. BioNixus provides planning intelligence and primary research around typical cycles and events — not a substitute for official procurement documents.',
    },
    {
      question: 'Is this the same as the NUPCO tendering guide?',
      answer:
        'No. The blog tendering guide explains how NUPCO processes work. This page focuses on 2026 calendar and event planning plus when to run commercial research around those windows.',
    },
    {
      question: 'Can BioNixus support a specific NUPCO category?',
      answer:
        'Yes. We design category-specific win/loss, ICV diligence, and hospital pull-through modules timed to your framework windows.',
    },
  ],
  areaServed: ['Saudi Arabia'],
  priority: 'now',
};

/* ------------------------------------------------------------------ */
/* NEXT                                                               */
/* ------------------------------------------------------------------ */

const singaporeIvdMarketAccess: SpecialtyMarketDemandContent = {
  slug: 'singapore-ivd-market-access',
  segmentLabel: 'Singapore IVD Market Access',
  badge: 'Singapore · IVD Access',
  breadcrumbLabel: 'Singapore IVD Market Access',
  title: 'Singapore IVD Market Access: HSA, Labs & Hospitals',
  description:
    'Singapore IVD market access: HSA pathways, SingHealth/NUHS/NHG lab algorithms, and assays that stay registered but unused. Primary research. 48h proposal.',
  canonical: `${BASE}/singapore-ivd-market-access`,
  h1: 'Singapore IVD market access',
  dateModified: '2026-11-04',
  geoAnswer:
    'Singapore IVD market access means HSA registration plus SingHealth, NUHS, or NHG laboratory validation, algorithm inclusion, and procurement — assays can be registered yet unused if lab directors never adopt them.',
  intro: [
    'Singapore IVD market access is decided inside hospital laboratories and cluster testing algorithms as much as at HSA registration. An assay can sit on the register and still miss SingHealth, NUHS, or NHG menus if lab directors, pathologists, and cluster procurement do not adopt it. We interview those buyers, map algorithm lock-in, and separate registered-but-unused SKUs from assays that actually run.',
    'APAC headquarters often pilot IVD stories in Singapore before ASEAN scale — but cluster standardisation means local lab behaviour is the binding constraint. BioNixus links Singapore access modules to Malaysia or GCC sequencing only when dossier travel is realistic.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  earlyLinks: [
    { to: '/insights/top-market-research-companies-singapore-2026', label: 'Singapore market research companies ranking' },
    { to: '/pharmaceutical-companies-singapore', label: 'pharmaceutical companies in Singapore' },
  ],
  decisionBlueprint: {
    why: 'IVD revenue in Singapore is lost at the lab menu, not at registration — cluster algorithms bind sister hospitals once a platform wins.',
    evidence:
      'Lab director and pathologist interviews show where validation burden, turnaround expectations, and reagent economics block adoption after HSA clearance.',
    next: 'Define the assay class and target clusters, map installed analysers, then run lab-leadership qual before clinician message tests.',
  },
  proofMetrics: [
    { label: 'Multi-gate access', detail: 'HSA, lab validation, clinical ordering, and procurement must align for volume.' },
    { label: 'Cluster standardisation', detail: 'Winning one cluster lab menu can bind multiple hospitals — or lock out challengers for years.' },
  ],
  deliveryPriorities: [
    'Cluster-specific lab and procurement map within two weeks.',
    'Qual with lab directors and pathologists before ordering-specialist modules.',
    'Registered-vs-running SKU diagnostic in the readout deck.',
  ],
  researchTopics: [
    {
      name: 'Lab director & pathologist interviews',
      detail: 'Algorithm fit, turnaround, trust barriers, and method-validation workload for new assays.',
    },
    {
      name: 'HSA IVD pathway mapping',
      detail: 'Classification and evidence expectations for commercial sequencing and high-complexity tests.',
    },
    {
      name: 'Cluster lab procurement',
      detail: 'SingHealth / NUHS / NHG tender and standardization logic for platforms and assays.',
    },
    {
      name: 'Competitive installed-base research',
      detail: 'Analyser platforms and switching costs that lock share across sister hospitals.',
    },
    {
      name: 'Clinical utility message testing',
      detail: 'What changes ordering behaviour among oncology and other ordering specialists.',
    },
    {
      name: 'ASEAN expansion linkage',
      detail: 'When Singapore IVD dossiers and lab credibility travel into ASEAN tenders.',
    },
  ],
  demandDrivers: {
    heading: 'Access drivers for IVD in Singapore',
    drivers: [
      { title: 'Cluster lab consolidation', detail: 'Central labs tighten platform and assay standardisation.' },
      { title: 'Precision oncology demand', detail: 'Companion and high-complexity tests raise evidence bars.' },
      { title: 'Cost-per-test scrutiny', detail: 'Procurement weighs reagent rental and throughput closely.' },
      { title: 'Point-of-care expansion', detail: 'Ward and clinic settings create parallel buyer sets.' },
      { title: 'Quality accreditation pressure', detail: 'Accreditation drives method validation timelines.' },
      { title: 'Regional HQ spotlight', detail: 'APAC teams pilot IVD stories in Singapore before ASEAN scale.' },
    ],
  },
  marketStructure: {
    heading: 'IVD access structure in Singapore',
    paragraphs: [
      'Access is multi-gated: HSA clearance, lab technical validation, clinical ordering behaviour, and budget owners. BioNixus scopes research to the gate that is currently blocking volume.',
      'Private hospitals may adopt faster than public clusters, but reagent contracts still bind platforms for multi-year horizons.',
      'Manufacturers should not treat Singapore registration as ASEAN access — BioNixus documents where reference and lab behaviour actually transfer.',
    ],
  },
  methodologyParagraphs: [
    'Respondent verification covers cluster affiliation, lab role, and platform responsibility. Programs triangulate lab leadership interviews with optional ordering-specialist modules when clinical pull is the stated bottleneck.',
  ],
  signalGrid: {
    heading: 'Cluster and lab signals',
    items: [
      { label: 'SingHealth clusters', signal: 'Strong central lab governance — algorithm changes ripple across institutions.' },
      { label: 'NUHS / NHG networks', signal: 'Parallel but distinct procurement calendars and validation committees.' },
      { label: 'Private hospital labs', signal: 'Faster pilots — useful for early evidence before public cluster bids.' },
      { label: 'HSA IVD register', signal: 'Necessary but insufficient — BioNixus tracks registered-vs-running gaps.' },
    ],
  },
  audiences: [
    { audience: 'Lab directors & pathologists', description: 'Technical and clinical gatekeepers for assay adoption.' },
    { audience: 'Hospital procurement', description: 'Buyers scoring contracts, reagent deals, and service.' },
    { audience: 'Ordering specialists', description: 'Oncologists and other clinicians who create pull.' },
    { audience: 'IVD commercial / medical teams', description: 'Teams building Singapore and ASEAN access plans.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/insights/top-market-research-companies-singapore-2026', label: 'Top market research companies in Singapore 2026' },
    { to: '/pharmaceutical-companies-singapore', label: 'Pharmaceutical companies in Singapore' },
    { to: '/clinical-diagnostics-market-research', label: 'Clinical diagnostics market research' },
    { to: '/singapore-medtech-manufacturing-market', label: 'Singapore MedTech manufacturing market' },
    { to: '/singapore-medical-devices-market-report', label: 'Singapore medical devices market report' },
  ],
  faqs: [
    {
      question: 'What is Singapore IVD market access?',
      answer:
        'Singapore IVD market access is HSA registration plus lab validation, cluster algorithm inclusion, and procurement so an assay actually runs at SingHealth, NUHS, or NHG — not only sits on the register.',
    },
    {
      question: 'What does IVD market access mean in Singapore?',
      answer:
        'It means clearing regulatory, laboratory validation, clinical ordering, and procurement gates so assays generate sustained volume — not only HSA listing.',
    },
    {
      question: 'Who decides IVD adoption in Singapore hospitals?',
      answer:
        'Typically laboratory leadership plus clinical champions and procurement — with cluster standardization often binding sister hospitals.',
    },
    {
      question: 'How does BioNixus research Singapore IVD access?',
      answer:
        'Primary interviews with verified lab directors, pathologists, and procurement stakeholders — mapped to cluster and platform context.',
    },
  ],
  areaServed: ['Singapore'],
  priority: 'next',
};

const japanNeurologyDevices: SpecialtyMarketDemandContent = {
  slug: 'japan-neurology-devices-market',
  segmentLabel: 'Japan Neurology Devices',
  badge: 'Japan · Neurology Devices',
  breadcrumbLabel: 'Japan Neurology Devices Market',
  title: 'Japan Neurology Devices Market Research 2026 | BioNixus',
  description:
    'Japan neurology devices market: stroke intervention, neurosurgery capital, PMDA pathways, and NHI category intelligence. Primary HCP and hospital research. 48h proposal.',
  canonical: `${BASE}/japan-neurology-devices-market`,
  h1: 'Japan Neurology Devices Market: Clinical & Access Intelligence',
  dateModified: '2026-11-04',
  geoAnswer:
    'Japan’s neurology devices market clusters in stroke networks, neurointervention, neurosurgery capital, and neuromonitoring — inside a high-bed, aging system where PMDA clearance and NHI reimbursement categories shape adoption faster than brand spend.',
  intro: [
    'Japan’s neurology devices market concentrates in stroke intervention, neurosurgery, monitoring, and implant categories inside a high-bed, aging health system. BioNixus isolates neurology from general MedTech coverage so OEMs can brief PMDA timing, NHI category issues, and hospital KOL cascades accurately.',
    'Teams searching the Japan neurology devices market need account-level protocol maps — which designated stroke centres set regional norms, how proctoring bandwidth limits diffusion, and where capital committees defer neuro purchases. We interview neurointerventionalists, stroke unit leads, biomedical engineering, and procurement with verified credentials.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  earlyLinks: [
    { to: '/japan-medical-devices-market-report', label: 'Japan medical devices market report' },
    { to: '/healthcare-market-research-japan', label: 'healthcare market research Japan' },
  ],
  decisionBlueprint: {
    why: 'Neurology device share in Japan follows stroke-network protocols and proctoring capacity — launches that ignore KOL cascade timing stall even after PMDA clearance.',
    evidence:
      'Primary research separates capital versus disposable economics under NHI categories and documents training objections that syndicated share data cannot explain.',
    next: 'Pick one device class (interventional, monitoring, or capital), map top stroke and neurosurgery accounts, and run KOL plus committee interviews before scaling quant.',
  },
  proofMetrics: [
    { label: 'Stroke centre concentration', detail: 'A small set of designated centres sets regional protocol templates.' },
    { label: 'Proctoring bandwidth', detail: 'Training capacity — not price alone — gates adoption beyond early adopters.' },
  ],
  deliveryPriorities: [
    'Account map aligned to stroke designation and neurosurgery volume tiers.',
    'Qual depth with neurointerventionalists and stroke coordinators in each target region.',
    'Competitive objection library tied to training, complication, and service themes.',
  ],
  researchTopics: [
    {
      name: 'Neurointerventionalist panels',
      detail: 'Stroke and aneurysm device choice drivers, switch barriers, and protocol stickiness after guideline updates.',
    },
    {
      name: 'Neurosurgery capital planning',
      detail: 'How hospitals prioritise neuro capital budgets versus other service lines under DPC pressure.',
    },
    {
      name: 'PMDA evidence expectations',
      detail: 'Clinical data and predicate strategies for neuro devices — including lag-reduction reforms.',
    },
    {
      name: 'NHI category implications',
      detail: 'Pricing category effects on disposable versus capital mixes and reorder economics.',
    },
    {
      name: 'Stroke network mapping',
      detail: 'Which centres set protocol norms regionally and how referrals concentrate volume.',
    },
    {
      name: 'Competitive objection libraries',
      detail: 'Training, complication, and service themes that stall share gains after shortlist wins.',
    },
  ],
  demandDrivers: {
    heading: 'Demand drivers in Japan neurology devices',
    drivers: [
      { title: 'Aging stroke burden', detail: 'Demographic pressure lifts interventional and monitoring volume.' },
      { title: 'Stroke centre designation', detail: 'Network design concentrates device utilisation and KOL influence.' },
      { title: 'Device lag reduction', detail: 'Faster PMDA review raises expectations for near-concurrent launch planning.' },
      { title: 'Training intensity', detail: 'Proctoring bandwidth gates diffusion beyond early adopters.' },
      { title: 'Hospital cost scrutiny', detail: 'High-cost disposables face sharper total-cost-of-care review.' },
      { title: 'Domestic OEM presence', detail: 'Japanese manufacturers shape preference baselines and service expectations.' },
    ],
  },
  marketStructure: {
    heading: 'How Japan neurology device adoption is structured',
    paragraphs: [
      'Volume concentrates in designated stroke and university neurosurgery centres. Distributor technical specialists and proctors are part of the commercial system BioNixus maps alongside clinical preference.',
      'Capital and disposable decisions run on different committee clocks — research must separate them before fieldwork scopes.',
      'Regional stroke networks mean national averages mislead; BioNixus cells programmes by network and account tier.',
    ],
  },
  methodologyParagraphs: [
    'Feasibility validates neuro specialist incidence and hospital access before protocol lock. Mixed designs pair KOL interviews with broader clinician surveys only when sample frames support statistically useful cuts.',
  ],
  audiences: [
    { audience: 'Neurointerventionalists & neurosurgeons', description: 'Primary clinical decision makers.' },
    { audience: 'Stroke unit / ICU leads', description: 'Protocol and pathway influencers.' },
    { audience: 'Hospital procurement', description: 'Capital and disposable contract owners.' },
    { audience: 'Biomedical engineering', description: 'Maintenance and inventory stakeholders.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/japan-general-surgical-devices-market', label: 'Japan general surgical devices market' },
    { to: '/japan-medical-devices-market-report', label: 'Japan medical devices market report' },
    { to: '/healthcare-market-research-japan', label: 'Healthcare market research Japan' },
  ],
  faqs: [
    {
      question: 'What does the Japan neurology devices market include?',
      answer:
        'Neurointervention consumables and capital, neurosurgical instruments, neuromonitoring, and related implants — researched as a distinct decision set from broad MedTech.',
    },
    {
      question: 'How does PMDA clearance relate to neurology device uptake in Japan?',
      answer:
        'Clearance opens the regulatory door; NHI category, hospital protocol, and proctoring capacity determine paid utilisation. BioNixus maps those gates with hospital stakeholders.',
    },
    {
      question: 'How does BioNixus research Japan neurology devices?',
      answer:
        'Primary interviews and optional surveys with verified neuro specialists, stroke coordinators, and hospital buyers — scoped to one device class and account list.',
    },
  ],
  areaServed: ['Japan'],
  priority: 'next',
};

const japanMedicalDisposables: SpecialtyMarketDemandContent = {
  slug: 'japan-medical-disposables-market',
  segmentLabel: 'Japan Medical Disposables',
  badge: 'Japan · Disposables',
  breadcrumbLabel: 'Japan Medical Disposables Market',
  title: 'Japan Medical Disposables Market Research 2026 | BioNixus',
  description:
    'Japan medical disposables market research: hospital consumables, infection-control tenders, nursing workflow, and PMDA-aligned procurement. Primary fieldwork. 48h proposal.',
  canonical: `${BASE}/japan-medical-disposables-market`,
  h1: 'Japan Medical Disposables Market: Procurement & Adoption Intelligence',
  dateModified: '2026-11-04',
  geoAnswer:
    'The Japan medical disposables market is a high-volume hospital consumables segment governed by infection-control standards, nursing workflow, and group purchasing — not retail demand. BioNixus maps nursing, infection-control, and procurement stakeholders to show which SKUs earn permanent formulary status versus perpetual trial.',
  intro: [
    'Japan’s medical disposables market is high-volume, committee-governed, and sensitive to infection-control standards and total cost. BioNixus researches nursing, infection control, and procurement stakeholders to show which SKUs earn formulary permanency versus perpetual trial status.',
    'Searchers asking about the Japan medical disposables market usually need tender timing, dual-source rules, and nursing adoption barriers — not syndicated unit forecasts. We combine desk structure on MHLW infection-prevention guidance and hospital QI programmes with primary interviews across public university hospitals, regional medical centres, and selected private groups.',
    'Manufacturers exporting to the Gulf often pair Japan disposables intelligence with GCC tender modules because origin-of-manufacture and shortage history travel into NUPCO and MOHAP dossiers. BioNixus links Japan and GCC workstreams when that is on the critical path.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  earlyLinks: [
    { to: '/japan-medical-devices-market-report', label: 'Japan medical devices market report' },
    { to: '/healthcare-market-research-japan', label: 'healthcare market research Japan' },
  ],
  decisionBlueprint: {
    why: 'Disposable share in Japan is won or lost on nursing workflow and infection-control credibility — small unit-price gaps rarely overcome a failed ward trial or a procurement committee that remembers a shortage.',
    evidence:
      'Primary research with infection-control leads, ward managers, and purchasing shows which attributes (kit design, training burden, dual-source readiness) predict renewal after the first tender cycle.',
    next: 'Scope one category cell (for example drapes, antiseptics, or procedure packs), map the tender calendar for target accounts, and run a feasibility sprint before scaling quant.',
  },
  proofMetrics: [
    {
      label: 'Decision stakeholders per SKU',
      detail: 'Typically three lanes — infection control, nursing, procurement — each with veto power on standardization.',
    },
    {
      label: 'Tender vs preference split',
      detail: 'Group purchasing sets price bands; nursing preference determines whether awarded SKUs stay on the ward cart.',
    },
  ],
  deliveryPriorities: [
    'Feasibility and account map within two weeks of objective alignment.',
    'Mixed qual/quant modules sized to one disposable category — not a blended “hospital supplies” average.',
    'Executive readout with switching barriers, service expectations, and 90-day account priorities.',
  ],
  researchTopics: [
    {
      name: 'Infection-control product research',
      detail:
        'PPE, drapes, and antiseptic category choice drivers — including JIS-aligned specifications, QI audit history, and how hospitals document compliance for accreditation renewals.',
    },
    {
      name: 'Ward nursing preference studies',
      detail:
        'Usability and workflow friction on high-turn SKUs: opening sequences, disposal steps, and compatibility with existing carts and automation.',
    },
    {
      name: 'Hospital tender intelligence',
      detail:
        'How standardization, dual-source rules, and service-level penalties operate in university, regional, and private group contracts.',
    },
    {
      name: 'Private vs public account mix',
      detail:
        'Where volume and margin concentrate — and where private groups adopt faster than public clusters still bound to legacy kits.',
    },
    {
      name: 'Competitive switching barriers',
      detail:
        'Training, kit redesign costs, and contractual lock-ins that keep incumbents on formulary after price-undercut bids.',
    },
    {
      name: 'GCC export linkage',
      detail:
        'When Japanese disposable credentials and shortage history influence Gulf hospital qualification and dual-source policies.',
    },
  ],
  demandDrivers: {
    heading: 'Demand drivers in Japan hospital disposables',
    drivers: [
      {
        title: 'Infection prevention standards',
        detail: 'Hospital QI programmes and accreditation cycles sustain premium disposables demand even when unit prices rise.',
      },
      {
        title: 'Nursing workflow pressure',
        detail: 'Usability and time-on-task often outweigh small yen-per-unit gaps in committee scoring.',
      },
      {
        title: 'Central tendering',
        detail: 'Group purchasing compresses net prices and raises expectations for training, fill rates, and shortage response.',
      },
      {
        title: 'Aging inpatient volumes',
        detail: 'Bed utilisation keeps baseline consumable demand elevated across medical and surgical wards.',
      },
      {
        title: 'Domestic manufacturing',
        detail: 'Japanese suppliers remain default referents; foreign entrants must prove service depth and documentation quality.',
      },
      {
        title: 'Sustainability scrutiny',
        detail: 'Green procurement criteria appear in evaluations for select categories — especially packaging and reprocessing alternatives.',
      },
    ],
  },
  marketStructure: {
    heading: 'How Japan medical disposables purchasing works',
    paragraphs: [
      'Disposables decisions mix nursing preference, infection-control policy, and purchasing contracts. Successful research treats those lanes explicitly instead of averaging them into a single “hospital buyer” persona.',
      'Public clusters run predictable tender cycles; private groups may pilot faster but still require infection-control sign-off before scale. BioNixus maps account-level calendars rather than relying on national averages.',
      'Export-oriented manufacturers should separate domestic ward adoption from overseas tender narratives — the evidence packs differ even when the SKU is identical.',
    ],
  },
  methodologyParagraphs: [
    'Programmes begin with a single decision objective — defend share, win a tender, or qualify a new SKU — then size qual depth (typically twelve to eighteen interviews per stakeholder cell) and optional quant where incidence allows. Respondent verification covers facility type, role, and category responsibility before field starts.',
  ],
  signalGrid: {
    heading: 'Category and account signals',
    items: [
      { label: 'Infection-control committees', signal: 'Set policy baselines that outlast individual tender awards.' },
      { label: 'Group purchasing organisations', signal: 'Compress price but cannot override ward rejection of poor workflow kits.' },
      { label: 'Biomedical / materials management', signal: 'Score fill rates, back-order history, and substitution rules.' },
      { label: 'Private hospital groups', signal: 'Often first to trial premium kits that later diffuse to public accounts.' },
    ],
  },
  audiences: [
    { audience: 'Infection-control leads', description: 'Policy gatekeepers for many disposable categories.' },
    { audience: 'Ward nursing managers', description: 'Daily users who veto poor workflow products.' },
    { audience: 'Hospital procurement', description: 'Contract and standardization owners.' },
    { audience: 'Distributor partners', description: 'Logistics and service intermediaries.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/japan-general-surgical-devices-market', label: 'Japan general surgical devices market' },
    { to: '/japan-medical-devices-market-report', label: 'Japan medical devices market report' },
    { to: '/gcc-medical-devices-market-report', label: 'GCC medical devices market report' },
    { to: '/healthcare-market-research-japan', label: 'Healthcare market research Japan' },
  ],
  faqs: [
    {
      question: 'What is included in Japan medical disposables research?',
      answer:
        'High-turn hospital consumables — infection-control products, procedure packs, and related single-use categories — researched through nursing, infection control, and procurement lenses with tender and workflow context.',
    },
    {
      question: 'What is the Japan medical disposables market?',
      answer:
        'It is the hospital and clinic market for single-use medical supplies governed by infection-prevention policy, nursing workflow, and group purchasing — distinct from capital devices or retail health products.',
    },
    {
      question: 'Who decides disposable formulary status in Japanese hospitals?',
      answer:
        'Infection-control and nursing leaders set usability and policy requirements; procurement converts them into contracts and dual-source rules. BioNixus interviews both sides before quant modules.',
    },
    {
      question: 'How does BioNixus research Japan medical disposables?',
      answer:
        'We run primary interviews and optional surveys with verified hospital stakeholders, map tender calendars for target accounts, and deliver a decision readout — not syndicated shipment tables.',
    },
  ],
  areaServed: ['Japan'],
  priority: 'next',
};

const japanMedtechAccessAutomation: SpecialtyMarketDemandContent = {
  slug: 'japan-medical-device-market-access',
  segmentLabel: 'Japan Medical Device Market Access',
  badge: 'Japan · Access & Automation',
  breadcrumbLabel: 'Japan Medical Device Market Access',
  title: 'Japan Medical Device Market Access & Automation | BioNixus',
  description:
    'Japan medical device market access and medical automation research — PMDA pathways, NHI listing, hospital automation adoption, and procurement.',
  canonical: `${BASE}/japan-medical-device-market-access`,
  h1: 'Japan Medical Device Market Access & Medical Automation Intelligence',
  intro: [
    'Queries for “Japan medical device market access” and “Japan medical automation market” share one commercial intent: understand the gates between PMDA clearance and paid hospital use — including automation platforms that change staffing and capital calculus. BioNixus researches HTA-adjacent stakeholders, hospital CIOs/biomed teams, and clinicians to stress-test access and automation narratives together.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'PMDA-to-NHI pathway research', detail: 'Timing, evidence, and category strategy for access.' },
    { name: 'Hospital automation readiness', detail: 'Pharmacy, lab, and OR automation buyer maps.' },
    { name: 'CIO / biomed capital scoring', detail: 'How IT and engineering evaluate automation ROI.' },
    { name: 'Workforce substitution perceptions', detail: 'Nursing and pharmacist attitudes to automation.' },
    { name: 'Competitive access benchmarking', detail: 'Analogues that recently cleared or stalled.' },
    { name: 'Service & uptime value tests', detail: 'Contract attributes that win after list price.' },
  ],
  demandDrivers: {
    heading: 'Access & automation drivers',
    drivers: [
      { title: 'Labour shortages', detail: 'Automation pitched as staffing relief faces culture and budget filters.' },
      { title: 'Device lag reforms', detail: 'Faster PMDA review raises concurrent-launch expectations.' },
      { title: 'DPC / NHI cost pressure', detail: 'Hospitals demand clear productivity or outcome proof.' },
      { title: 'Digital hospital agendas', detail: 'CIO involvement intensifies for connected devices.' },
      { title: 'Cybersecurity diligence', detail: 'Connected automation faces longer IT review cycles.' },
      { title: 'Domestic competitor strength', detail: 'Japanese automation vendors set trust baselines.' },
    ],
  },
  marketStructure: {
    heading: 'Structure',
    paragraphs: [
      'Market access and automation purchases both require multi-stakeholder coalitions. BioNixus maps those coalitions and tests messages with each lane rather than averaging them into a single “hospital buyer” persona.',
    ],
  },
  audiences: [
    { audience: 'Hospital CIO / IT security', description: 'Connected-device and automation gatekeepers.' },
    { audience: 'Biomedical engineering', description: 'Uptime, integration, and maintenance owners.' },
    { audience: 'Clinical department heads', description: 'Productivity and safety claimants.' },
    { audience: 'Procurement / finance', description: 'Capital committee scorers.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/japan-medical-devices-market-report', label: 'Japan medical devices market report' },
    { to: '/japan-general-surgical-devices-market', label: 'Japan general surgical devices market' },
    { to: '/healthcare-bioconvergence-market', label: 'Healthcare bioconvergence market' },
  ],
  faqs: [
    {
      question: 'What is Japan medical device market access research?',
      answer:
        'Primary research that maps the practical gates from PMDA authorization to hospital payment and adoption — including committee evidence needs and automation-specific IT/workflow barriers.',
    },
  ],
  areaServed: ['Japan'],
  priority: 'next',
};

const italyClinicalTrials: SpecialtyMarketDemandContent = {
  slug: 'italy-clinical-trials-market',
  segmentLabel: 'Italy Clinical Trials Market',
  badge: 'Italy · Clinical Trials',
  breadcrumbLabel: 'Italy Clinical Trials Market',
  title: 'Italy Clinical Trials Market Research | BioNixus',
  description:
    'Italy clinical trials market research — site feasibility, ethics timelines, investigator networks, AIFA-aware context, and sponsor decision intelligence.',
  canonical: `${BASE}/italy-clinical-trials-market`,
  h1: 'Italy Clinical Trials Market: Site, Feasibility & Sponsor Intelligence',
  intro: [
    'Italy remains a major EU clinical-trial destination with dense university hospitals and specialty networks — but ethics timelines, site activation friction, and competitive enrolment determine real attractiveness. BioNixus researches investigators, site staff, and sponsor outsourcing stakeholders to support country selection and rescue decisions.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'Site feasibility & enrolment realism', detail: 'Indication-level speed and competition for patients.' },
    { name: 'Ethics / start-up intelligence', detail: 'Timeline and documentation friction by region and site type.' },
    { name: 'Investigator network mapping', detail: 'Which centres actually enrol versus claim capacity.' },
    { name: 'CRO / FSP perception research', detail: 'Sponsor and site views of delivery models in Italy.' },
    { name: 'Therapeutic area concentration', detail: 'Oncology, rare disease, and cardiology site strength.' },
    { name: 'EU CTR operational implications', detail: 'How CTR implementation is felt by sites and sponsors.' },
  ],
  demandDrivers: {
    heading: 'Demand drivers',
    drivers: [
      { title: 'EU CTR harmonisation', detail: 'Process changes alter relative attractiveness versus EU peers.' },
      { title: 'Oncology trial density', detail: 'Competition for patients forces sharper site selection.' },
      { title: 'Rare-disease expertise', detail: 'Specialty centres become capacity bottlenecks.' },
      { title: 'Sponsor cost pressure', detail: 'Feasibility realism valued over optimistic enrolments.' },
      { title: 'Startup timeline scrutiny', detail: 'Activation lag decides country inclusion.' },
      { title: 'Site staff bandwidth', detail: 'CRC capacity increasingly gates protocol complexity.' },
    ],
  },
  marketStructure: {
    heading: 'Structure',
    paragraphs: [
      'Italy’s trial market is hospital-led with regional variation in ethics and contracting maturity. BioNixus scopes feasibility to the indication and phase, not national averages.',
    ],
  },
  audiences: [
    { audience: 'Principal investigators', description: 'Enrolment and scientific gatekeepers.' },
    { audience: 'Site management / CRCs', description: 'Operational capacity and friction informants.' },
    { audience: 'Sponsor clinical operations', description: 'Country-selection decision owners.' },
    { audience: 'CRO / FSP leaders', description: 'Delivery-model competitors and partners.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/gcc-clinical-trials-market', label: 'GCC clinical trials market' },
    { to: '/healthcare-market-research-italy', label: 'Healthcare market research Italy' },
    { to: '/pharmaceutical-market-research-italy', label: 'Pharmaceutical market research Italy' },
    { to: '/italy-medical-devices-market-report', label: 'Italy MedTech market research' },
  ],
  faqs: [
    {
      question: 'Why run clinical trials market research in Italy?',
      answer:
        'To validate site speed, enrolment realism, and startup friction before committing country budgets — especially in competitive oncology and rare-disease indications.',
    },
  ],
  areaServed: ['Italy'],
  priority: 'next',
};

const mekInhibitors: SpecialtyMarketDemandContent = {
  slug: 'mek-inhibitors-market',
  segmentLabel: 'MEK Inhibitors Market Access',
  badge: 'Global / GCC · Oncology Access',
  breadcrumbLabel: 'MEK Inhibitors Market Access',
  title: 'MEK Inhibitors Market Access Research 2026 | BioNixus',
  description:
    'MEK inhibitors market access: biomarker testing, oncology sequencing, payer evidence, and GCC tender pull-through. Primary research with oncologists. 48h proposal.',
  canonical: `${BASE}/mek-inhibitors-market`,
  h1: 'MEK Inhibitors Market Access: Oncology Evidence & Commercial Intelligence',
  dateModified: '2026-11-04',
  geoAnswer:
    'MEK inhibitor market access depends on biomarker-ready oncology networks, line-of-therapy sequencing, and payer or tender gates — not awareness alone. BioNixus maps where MEK classes win protocol space and where testing or funding stalls uptake.',
  intro: [
    'MEK inhibitor access decisions turn on biomarker pathway readiness, line-of-therapy sequencing, and payer evidence — not brand awareness alone. BioNixus runs oncologist, molecular-pathology, and access interviews to show where MEK classes win protocol space and where testing or funding gates stall uptake, with GCC modules when tender listing is on the path.',
    'Combination regimens mean partner-drug access can gate MEK utilisation even after local registration. We design modules by indication cluster and geography rather than treating “MEK market” as one homogeneous category.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  earlyLinks: [
    { to: '/healthcare-market-research/therapy/oncology', label: 'oncology market research hub' },
    { to: '/real-world-evidence', label: 'real world evidence programmes' },
  ],
  decisionBlueprint: {
    why: 'MEK share is precision-oncology share — without molecular pathology capacity and funded testing, eligible patients never reach the prescription decision.',
    evidence:
      'Oncologist and pathologist interviews isolate sequencing choices, testing turnaround barriers, and payer objections that syndicated sales data cannot explain.',
    next: 'Pick indication cluster and geography, map testing and payer gates, then run qual before message or RWE modules.',
  },
  proofMetrics: [
    { label: 'Testing gate', detail: 'Turnaround and reflex testing policies often cap eligible pools before price is discussed.' },
    { label: 'Combination dependency', detail: 'Partner-drug access can stall MEK uptake even when the MEK label is cleared.' },
  ],
  deliveryPriorities: [
    'Indication-specific stakeholder map (oncology, pathology, access).',
    'GCC tender module when NUPCO or hospital listing is on the path.',
    'Objection library for medical affairs and access teams.',
  ],
  researchTopics: [
    {
      name: 'Oncologist treatment sequencing',
      detail: 'Where MEK sits versus competing targeted options by line and biomarker subgroup.',
    },
    {
      name: 'Biomarker testing readiness',
      detail: 'Molecular pathology capacity, reflex rules, and turnaround barriers.',
    },
    {
      name: 'Payer / HTA evidence expectations',
      detail: 'What dossiers must prove for funding in public and insured pathways.',
    },
    {
      name: 'GCC tender & formulary modules',
      detail: 'NUPCO and hospital listing dynamics for high-cost oncology combinations.',
    },
    {
      name: 'Patient-support & adherence',
      detail: 'Programme attributes that change real-world persistence on oral targeted therapy.',
    },
    {
      name: 'Competitive message testing',
      detail: 'Safety, efficacy, and convenience themes that move share in crowded sets.',
    },
  ],
  demandDrivers: {
    heading: 'MEK inhibitor access drivers',
    drivers: [
      { title: 'Precision-oncology expansion', detail: 'More tested patients create eligible pools — when labs keep up.' },
      { title: 'Combination regimens', detail: 'Partner drug access can gate MEK utilisation.' },
      { title: 'High-cost scrutiny', detail: 'Payers demand clearer sequencing rationale.' },
      { title: 'GCC framework awards', detail: 'Listing without pull-through leaves volume stranded.' },
      { title: 'Indication breadth', detail: 'Label expansions change competitive sets quickly.' },
      { title: 'RWE expectations', detail: 'Local evidence increasingly requested at committee.' },
    ],
  },
  marketStructure: {
    heading: 'How MEK access is structured',
    paragraphs: [
      'MEK access is oncology-network and testing-dependent. BioNixus designs modules by indication cluster and geography rather than treating “MEK market” as one homogeneous category.',
      'Hospital formulary, national payer, and tender channels can disagree — research must map which gate is binding in each target market.',
      'Medical affairs and access teams need separate readouts from the same field when messaging and dossier gaps diverge.',
    ],
  },
  methodologyParagraphs: [
    'Programs use verified oncologist and pathologist recruitment with documented testing-pathway questions. GCC modules add tender and pharmacy stakeholders when injectable or high-cost oral combinations move through frameworks.',
  ],
  audiences: [
    { audience: 'Medical oncologists', description: 'Prescribing decision owners.' },
    { audience: 'Molecular pathologists', description: 'Testing pathway gatekeepers.' },
    { audience: 'Hospital formulary / payers', description: 'Funding and listing stakeholders.' },
    { audience: 'Medical affairs / access teams', description: 'Evidence and messaging owners.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/febrile-neutropenia-market', label: 'Febrile neutropenia market' },
    { to: '/healthcare-market-research/therapy/oncology', label: 'Oncology market research' },
    { to: '/market-reports/gcc-oncology-market-report', label: 'GCC oncology market report' },
    { to: '/real-world-evidence', label: 'Real world evidence' },
  ],
  faqs: [
    {
      question: 'What is MEK inhibitors market access research?',
      answer:
        'Primary research with oncology, pathology, and funding stakeholders that maps the practical barriers between regulatory approval and sustained utilisation for MEK inhibitor classes.',
    },
    {
      question: 'Why do MEK inhibitors stall after approval?',
      answer:
        'Common blockers are biomarker testing capacity, sequencing choices, combination partner access, and payer or tender pull-through — BioNixus maps which gate binds in your target market.',
    },
    {
      question: 'Does BioNixus cover MEK access in the GCC?',
      answer:
        'Yes — optional modules cover NUPCO frameworks, hospital formulary behaviour, and oncology pharmacy substitution when Gulf listing is on the path.',
    },
  ],
  priority: 'next',
};

const febrileNeutropenia: SpecialtyMarketDemandContent = {
  slug: 'febrile-neutropenia-market',
  segmentLabel: 'Febrile Neutropenia Market',
  badge: 'Global / GCC · Supportive Care',
  breadcrumbLabel: 'Febrile Neutropenia Market',
  title: 'Febrile Neutropenia Market Research 2026 | BioNixus',
  description:
    'Febrile neutropenia market research: G-CSF prophylaxis protocols, biosimilar switching, oncology pharmacy tenders, and GCC supportive-care intelligence. 48h proposal.',
  canonical: `${BASE}/febrile-neutropenia-market`,
  h1: 'Febrile Neutropenia Market: Supportive-Care & Protocol Intelligence',
  dateModified: '2026-11-04',
  geoAnswer:
    'The febrile neutropenia market is driven by oncology regimen intensity, hospital prophylaxis protocols, and biosimilar G-CSF competition — BioNixus maps oncologist, pharmacy, and tender behaviour rather than syndicated unit forecasts.',
  intro: [
    'The febrile neutropenia market is driven by oncology regimen intensity, hospital prophylaxis protocols, and biosimilar G-CSF competition more than consumer awareness. BioNixus researches oncologists, oncology pharmacists, and tender stakeholders to forecast switching and protocol stickiness — including Gulf hospital settings where supportive-care injectables move through frameworks.',
    'Prophylaxis versus secondary treatment decisions, pegfilgrastim versus filgrastim formats, and day-clinic expansion all change the addressable pool. We scope FN, G-CSF, and admission pathway questions separately before fieldwork.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  earlyLinks: [
    { to: '/healthcare-market-research/therapy/oncology', label: 'oncology market research hub' },
    { to: '/gcc-generic-injectables-market', label: 'GCC generic injectables market' },
  ],
  decisionBlueprint: {
    why: 'G-CSF share follows oncology protocol and pharmacy substitution rules — tender wins without protocol pull-through revert within a cycle.',
    evidence:
      'Oncologist and oncology pharmacist interviews show prophylaxis thresholds, biosimilar confidence, and shortage-driven dual-source policies that drive real utilisation.',
    next: 'Define geography and care setting (inpatient vs day clinic), map tender calendars, then run pharmacy and oncologist qual.',
  },
  proofMetrics: [
    { label: 'Protocol gate', detail: 'Primary vs secondary prophylaxis rules set the eligible patient pool.' },
    { label: 'Pharmacy substitution', detail: 'Tender awards trigger rapid switches when pharmacists control injectable brands.' },
  ],
  deliveryPriorities: [
    'Separate prophylaxis, treatment, and tender modules in the research design.',
    'GCC framework add-on when NUPCO or hospital awards are relevant.',
    'Switching and shortage narrative testing for medical affairs.',
  ],
  researchTopics: [
    {
      name: 'Prophylaxis protocol research',
      detail: 'When hospitals choose primary vs secondary prophylaxis by regimen and risk score.',
    },
    {
      name: 'G-CSF brand / biosimilar switching',
      detail: 'Pharmacist and oncologist confidence drivers after tender or shortage events.',
    },
    {
      name: 'Inpatient pathway mapping',
      detail: 'Admission and antibiotic pathway implications for brand choice.',
    },
    {
      name: 'GCC tender modules',
      detail: 'Framework dynamics for supportive-care injectables in Saudi and UAE hospitals.',
    },
    {
      name: 'Nursing administration friction',
      detail: 'Device and schedule attributes that affect preference in day-clinic expansion.',
    },
    {
      name: 'Competitive message tests',
      detail: 'Safety, convenience, and supply themes that move share after formulary listing.',
    },
  ],
  demandDrivers: {
    heading: 'Febrile neutropenia and G-CSF demand drivers',
    drivers: [
      { title: 'Myelosuppressive regimens', detail: 'Oncology protocol mix sets the addressable prophylaxis pool.' },
      { title: 'Biosimilar pressure', detail: 'Hospital pharmacies accelerate switches after tender change.' },
      { title: 'Length-of-stay objectives', detail: 'Hospitals value regimens that reduce FN admissions.' },
      { title: 'Supply reliability', detail: 'Shortage history influences dual-source policies.' },
      { title: 'Day-clinic expansion', detail: 'Outpatient oncology changes administration preferences.' },
      { title: 'Guideline updates', detail: 'Society guidance shifts prophylaxis thresholds.' },
    ],
  },
  marketStructure: {
    heading: 'How FN and G-CSF markets are structured',
    paragraphs: [
      'FN markets are protocol- and tender-shaped. BioNixus isolates prophylaxis choice, secondary treatment, and tender award as distinct research questions.',
      'Supportive-care injectables in the GCC move through framework awards — listing and pull-through must be researched separately.',
      'Oncology network leaders set prophylaxis norms that pharmacy tenders cannot override without clinical sign-off.',
    ],
  },
  methodologyParagraphs: [
    'Feasibility confirms oncologist and oncology pharmacist incidence by country. Quant modules attach only when a single protocol or tender decision is the stated objective.',
  ],
  audiences: [
    { audience: 'Medical oncologists', description: 'Protocol decision owners.' },
    { audience: 'Oncology pharmacists', description: 'Substitution and tender influencers.' },
    { audience: 'Hospital infectious disease', description: 'Admission pathway stakeholders.' },
    { audience: 'Procurement / tenders', description: 'Framework and award decision makers.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/mek-inhibitors-market', label: 'MEK inhibitors market access' },
    { to: '/gcc-generic-injectables-market', label: 'GCC generic injectables market' },
    { to: '/healthcare-market-research/therapy/oncology', label: 'Oncology market research' },
    { to: '/market-reports/gcc-oncology-market-report', label: 'GCC oncology market report' },
  ],
  faqs: [
    {
      question: 'What drives the febrile neutropenia market?',
      answer:
        'Oncology regimen myelosuppression, prophylaxis guidelines, hospital pharmacy substitution, and tender awards for G-CSF and related supportive care — researched by BioNixus through clinical and procurement stakeholders.',
    },
    {
      question: 'What is febrile neutropenia market research?',
      answer:
        'Primary research on prophylaxis protocols, G-CSF brand and biosimilar switching, and tender dynamics — scoped to the countries and care settings on your launch plan.',
    },
    {
      question: 'Does BioNixus research G-CSF tenders in the GCC?',
      answer:
        'Yes — optional modules cover framework awards, hospital pharmacy substitution, and pull-through after listing for supportive-care injectables.',
    },
  ],
  priority: 'next',
};

/* ------------------------------------------------------------------ */
/* LATER                                                              */
/* ------------------------------------------------------------------ */

const italyPortableDiagnostics: SpecialtyMarketDemandContent = {
  slug: 'italy-portable-diagnostic-devices-market',
  segmentLabel: 'Italy Portable Diagnostic Devices',
  badge: 'Italy · Portable Diagnostics',
  breadcrumbLabel: 'Italy Portable Diagnostic Devices Market',
  title: 'Italy Portable Diagnostic Devices Market 2026 | BioNixus',
  description:
    'Italy portable diagnostic devices market: POCT adoption, ED and ward pathways, AIFA context, and regional hospital procurement. Primary research. 48h proposal.',
  canonical: `${BASE}/italy-portable-diagnostic-devices-market`,
  h1: 'Italy Portable Diagnostic Devices Market: POCT & Adoption Intelligence',
  dateModified: '2026-11-04',
  geoAnswer:
    'Italy’s portable diagnostic devices market is shaped by hospital POCT programmes, community lab networks, and regional procurement — BioNixus maps lab directors, ED clinicians, and ASL buyers to show which platforms scale beyond pilot.',
  intro: [
    'Italy’s portable diagnostic devices market is shaped by hospital POCT programmes, community laboratory networks, and regional procurement rules more than retail gadget demand. BioNixus researches laboratory directors, emergency and ward clinicians, and ASL/hospital buyers to show which handheld and near-patient platforms clear volume — and which remain pilots.',
    'Queries for the Italy portable diagnostic devices market reflect POCT and near-patient testing intent — buyers need validation burden, LIS connectivity, and reagent economics, not consumer gadget reviews.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  earlyLinks: [
    { to: '/italy-medical-devices-market-report', label: 'Italy medical devices market report' },
    { to: '/healthcare-market-research-italy', label: 'healthcare market research Italy' },
  ],
  decisionBlueprint: {
    why: 'POCT share in Italy is won in the lab validation queue and ED pathway design — devices that fail LIS integration never leave the pilot ward.',
    evidence:
      'Lab director and ED lead interviews document method-validation workload, connectivity requirements, and regional tender scoring that syndicated install counts miss.',
    next: 'Pick acute vs ambulatory pathway, map regional buyers, then run lab-governance qual before clinician pull modules.',
  },
  proofMetrics: [
    { label: 'Lab governance gate', detail: 'Quality and validation committees control scale beyond single-ward pilots.' },
    { label: 'Regional tender variation', detail: 'ASL and hospital group specs differ on connectivity and service clauses.' },
  ],
  deliveryPriorities: [
    'Pathway-specific sample frame (ED, ward, ambulatory).',
    'Regional procurement calendar where tenders are the binding gate.',
    'Installed-base and switching cost map for competing platforms.',
  ],
  researchTopics: [
    {
      name: 'POCT programme mapping',
      detail: 'Where Italy hospitals authorize, train, and govern near-patient testing by region and account type.',
    },
    {
      name: 'Lab director adoption research',
      detail: 'Quality, connectivity, and reagent-contract barriers to scale after successful pilots.',
    },
    {
      name: 'Clinical pathway interviews',
      detail: 'ED, ward, and ambulatory use cases that create sustained ordering pull.',
    },
    {
      name: 'Regional procurement signals',
      detail: 'How regional tenders and hospital groups score portable platforms and service.',
    },
    {
      name: 'Competitive installed-base research',
      detail: 'Switch costs versus benchtop and central-lab alternatives.',
    },
    {
      name: 'EU MDR / IVDR evidence needs',
      detail: 'Documentation and PMS expectations that affect Italy timelines.',
    },
  ],
  demandDrivers: {
    heading: 'Italy portable diagnostics demand drivers',
    drivers: [
      { title: 'ED and ward turnaround pressure', detail: 'Faster decisions favour near-patient panels when quality holds.' },
      { title: 'Workforce constraints', detail: 'Staffing shortages raise interest in compact workflows.' },
      { title: 'Regional lab consolidation', detail: 'Central labs reassess which tests stay decentralised.' },
      { title: 'Chronic ambulatory monitoring', detail: 'Cardiometabolic and respiratory use cases expand beyond acute care.' },
      { title: 'Reagent rental economics', detail: 'Total cost and throughput decide renewals more than list price.' },
      { title: 'Connectivity expectations', detail: 'LIS/HIS integration is now a table-stakes evaluation criterion.' },
    ],
  },
  marketStructure: {
    heading: 'Italy POCT and portable diagnostics structure',
    paragraphs: [
      'Portable diagnostics in Italy sit between laboratory governance and clinical urgency. BioNixus separates acute POCT, ambulatory programmes, and community pathways so manufacturers do not average incompatible buyer sets.',
      'Regionalisation means Lombardy, Lazio, and Campania buyers can follow different tender rhythms — national slides mislead without primary validation.',
    ],
  },
  methodologyParagraphs: [
    'Programs verify lab role, pathway ownership, and platform responsibility before interviews. Optional quant attaches when a single tender or protocol decision is scoped.',
  ],
  signalGrid: {
    heading: 'Regional and pathway signals',
    items: [
      { label: 'University hospital labs', signal: 'Strong validation discipline — longer pilots but sticky adoption.' },
      { label: 'ED-heavy centres', signal: 'Turnaround pressure drives POCT pull when lab directors agree.' },
      { label: 'Regional ASL procurement', signal: 'Tender clauses increasingly specify interoperability.' },
      { label: 'Ambulatory networks', signal: 'Chronic-care POCT grows where reimbursement supports home and clinic testing.' },
    ],
  },
  audiences: [
    { audience: 'Laboratory directors', description: 'Quality and method-validation gatekeepers.' },
    { audience: 'ED / ward clinical leads', description: 'Pathway owners who create ordering pull.' },
    { audience: 'Hospital / ASL procurement', description: 'Contract and tender decision makers.' },
    { audience: 'IT / connectivity owners', description: 'Integration and cybersecurity reviewers.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/italy-clinical-trials-market', label: 'Italy clinical trials market' },
    { to: '/italy-medical-device-connectivity-market', label: 'Italy medical device connectivity market' },
    { to: '/italy-medical-devices-market-report', label: 'Italy MedTech market research' },
    { to: '/clinical-diagnostics-market-research', label: 'Clinical diagnostics market research' },
    { to: '/pharmaceutical-market-research-italy', label: 'Pharmaceutical market research Italy' },
    { to: '/healthcare-market-research-italy', label: 'Healthcare market research Italy' },
  ],
  faqs: [
    {
      question: 'What is the Italy portable diagnostic devices market?',
      answer:
        'Near-patient and handheld diagnostic platforms used in hospitals, ambulatory settings, and selected community pathways — researched through laboratory, clinical, and procurement stakeholders rather than consumer gadget panels.',
    },
    {
      question: 'What is Italy portable diagnostic devices market research?',
      answer:
        'Primary research on POCT governance, regional procurement, and clinical pathway pull — scoped to the accounts and regions on your commercial plan.',
    },
    {
      question: 'How does IVDR affect portable diagnostics in Italy?',
      answer:
        'IVDR documentation and post-market surveillance expectations shape validation timelines — BioNixus maps buyer diligence themes alongside regulatory context.',
    },
  ],
  areaServed: ['Italy'],
  priority: 'later',
};

const italyDeviceConnectivity: SpecialtyMarketDemandContent = {
  slug: 'italy-medical-device-connectivity-market',
  segmentLabel: 'Italy Medical Device Connectivity',
  badge: 'Italy · Digital Health / Connectivity',
  breadcrumbLabel: 'Italy Medical Device Connectivity Market',
  title: 'Italy Medical Device Connectivity Market 2026 | BioNixus',
  description:
    'Italy medical device connectivity market: HIS/LIS integration, hospital IT diligence, cybersecurity gates, and digital health procurement. Primary research. 48h proposal.',
  canonical: `${BASE}/italy-medical-device-connectivity-market`,
  h1: 'Italy Medical Device Connectivity & Digital Health Market Intelligence',
  dateModified: '2026-11-04',
  geoAnswer:
    'Italy medical device connectivity market research maps who funds, integrates, and approves connected devices inside hospital IT stacks — CIO, clinical engineering, and cybersecurity veto go-live as often as clinical sponsors.',
  intro: [
    'Queries for “Italy medical device connectivity market” and “Italy microservices healthcare market” point to the same commercial gap: who funds, integrates, and greets connected devices inside Italian hospital IT stacks. BioNixus interviews CIOs, clinical engineering, cybersecurity, and department heads to test whether connectivity claims survive procurement and go-live.',
    'MDR post-market surveillance and regional tender clauses increasingly require interoperability evidence — manufacturers need coalition maps, not feature lists.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  earlyLinks: [
    { to: '/italy-portable-diagnostic-devices-market', label: 'Italy portable diagnostic devices market' },
    { to: '/healthcare-market-research-italy', label: 'healthcare market research Italy' },
  ],
  decisionBlueprint: {
    why: 'Connected device revenue in Italy is an IT approval problem — clinical enthusiasm without cybersecurity and LIS sign-off produces shelfware.',
    evidence:
      'CIO and clinical engineering interviews reveal interface requirements, patching expectations, and architecture preferences that marketing claims rarely survive.',
    next: 'Define device class and target regions, map IT coalition, then test interoperability evidence packs before clinical message modules.',
  },
  proofMetrics: [
    { label: 'Coalition buy', detail: 'CIO, CISO, clinical engineering, and department heads each hold veto power.' },
    { label: 'Tender interoperability clauses', detail: 'Regional specs increasingly bind vendors to named interfaces and uptime SLAs.' },
  ],
  deliveryPriorities: [
    'IT and clinical engineering qual before clinician-only modules.',
    'Cybersecurity evidence pack review against buyer checklists.',
    'Regional tender language scan for interoperability requirements.',
  ],
  researchTopics: [
    {
      name: 'HIS / LIS / PACS integration research',
      detail: 'What interfaces and middleware hospitals actually require — not vendor roadmap slides.',
    },
    {
      name: 'Microservices & architecture diligence',
      detail: 'How IT teams evaluate modular vs monolithic vendor stacks for device data.',
    },
    {
      name: 'Cybersecurity and GDPR review gates',
      detail: 'Evidence packs that unblock connected-device tenders and go-live.',
    },
    {
      name: 'Clinical engineering workflows',
      detail: 'Uptime, patching, and fleet-management expectations for connected fleets.',
    },
    {
      name: 'Department buying coalitions',
      detail: 'Who sponsors connectivity spend beyond the central IT budget.',
    },
    {
      name: 'Competitive objection libraries',
      detail: 'Why incumbents retain share after RFP shortlists despite feature parity.',
    },
  ],
  demandDrivers: {
    heading: 'Italy connectivity and digital health drivers',
    drivers: [
      { title: 'Hospital digitalisation agendas', detail: 'National and regional digital health programmes raise integration expectations.' },
      { title: 'Cybersecurity scrutiny', detail: 'Connected fleets face longer IT approval cycles.' },
      { title: 'Staffing productivity pressure', detail: 'Automation and remote monitoring need clean data plumbing.' },
      { title: 'Vendor consolidation', detail: 'Hospitals prefer fewer platforms with proven interfaces.' },
      { title: 'MDR PMS / data obligations', detail: 'Post-market surveillance pushes better device data capture.' },
      { title: 'Regional tender complexity', detail: 'Specifications increasingly include interoperability clauses.' },
    ],
  },
  marketStructure: {
    heading: 'Connectivity purchasing structure in Italy',
    paragraphs: [
      'Connectivity purchases are coalition buys across IT, clinical engineering, and clinical departments. BioNixus maps those coalitions and tests microservices/interoperability claims with the people who can veto go-live.',
      'Regional health systems differ in IT maturity — Lombardy and Emilia-Romagna hospital groups often move faster than smaller ASL networks with legacy HIS stacks.',
    ],
  },
  methodologyParagraphs: [
    'Respondent verification covers IT role, facility type, and connected-device portfolio responsibility. Programs separate capital connectivity from SaaS monitoring to avoid mixed buyer sets.',
  ],
  signalGrid: {
    heading: 'IT and procurement signals',
    items: [
      { label: 'CIO / IT architecture', signal: 'Sets interface standards and middleware choices that bind device vendors.' },
      { label: 'Cybersecurity offices', signal: 'Risk acceptance documents now common for connected fleets.' },
      { label: 'Clinical engineering', signal: 'Owns uptime, patching, and fleet maintenance SLAs.' },
      { label: 'Regional tenders', signal: 'Interoperability and cybersecurity clauses appear in MedTech RFPs.' },
    ],
  },
  audiences: [
    { audience: 'Hospital CIO / IT architecture', description: 'Integration and platform decision owners.' },
    { audience: 'Cybersecurity leads', description: 'Gatekeepers for connected-device risk acceptance.' },
    { audience: 'Clinical engineering', description: 'Fleet, uptime, and maintenance stakeholders.' },
    { audience: 'Clinical department heads', description: 'Sponsors who create budget and workflow pull.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/italy-portable-diagnostic-devices-market', label: 'Italy portable diagnostic devices market' },
    { to: '/italy-clinical-trials-market', label: 'Italy clinical trials market' },
    { to: '/italy-medical-devices-market-report', label: 'Italy MedTech market research' },
    { to: '/healthcare-bioconvergence-market', label: 'Healthcare bioconvergence market' },
    { to: '/healthcare-market-research-italy', label: 'Healthcare market research Italy' },
    { to: '/japan-medical-device-market-access', label: 'Japan medical device market access' },
  ],
  faqs: [
    {
      question: 'What does Italy medical device connectivity research cover?',
      answer:
        'Primary research on how Italian hospitals evaluate device-to-HIS/LIS integration, microservices architectures, cybersecurity, and clinical go-live — the gates that decide whether connected MedTech actually deploys.',
    },
    {
      question: 'What is the Italy medical device connectivity market?',
      answer:
        'Hospital and regional spending on integrating connected devices, remote monitoring platforms, and digital health middleware — researched through IT, clinical engineering, and clinical sponsors.',
    },
    {
      question: 'How does BioNixus research Italy device connectivity?',
      answer:
        'Verified interviews with CIO, cybersecurity, clinical engineering, and department stakeholders — mapped to regional tender and architecture context.',
    },
  ],
  areaServed: ['Italy'],
  priority: 'later',
};

const italyOncologyAntiInfectiveAccess: SpecialtyMarketDemandContent = {
  slug: 'italy-oncology-antiinfective-market-access',
  segmentLabel: 'Italy Oncology & Anti-infective Access',
  badge: 'Italy · Oncology / Anti-infective Access',
  breadcrumbLabel: 'Italy Oncology & Anti-infective Market Access',
  title: 'Italy Oncology & Anti-infective Market Access Research | BioNixus',
  description:
    'Italy oncology and anti-infective market access research — Keytruda-class IO analogues, daptomycin-class hospital antibiotics, AIFA/regional pathways, and.',
  canonical: `${BASE}/italy-oncology-antiinfective-market-access`,
  h1: 'Italy Oncology & Anti-infective Market Access: AIFA, Hospital & Regional Intelligence',
  intro: [
    'Search interest in “Italy Keytruda market” and “Italy daptomycin market” is access intent: how IO and high-value hospital anti-infectives clear AIFA, regional, and hospital formulary gates. BioNixus runs oncologist, infectious-disease, hospital pharmacy, and access interviews so commercial teams see protocol share and funding friction separately — not as a single national average.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'IO / Keytruda-class access mapping', detail: 'Indication sequencing, biomarker testing, and regional funding friction.' },
    { name: 'Hospital antibiotic formulary research', detail: 'Daptomycin-class stewardship, substitution, and tender dynamics.' },
    { name: 'AIFA and regional pathway interviews', detail: 'What evidence and negotiation realities shape listing timelines.' },
    { name: 'Hospital P&T behaviour', detail: 'How pharmacy and clinical committees convert listing into protocol use.' },
    { name: 'Competitive analogue libraries', detail: 'Messaging and objection themes in crowded IO and anti-infective sets.' },
    { name: 'RWE expectations', detail: 'Local evidence requests that delay or accelerate uptake.' },
  ],
  demandDrivers: {
    heading: 'Access drivers',
    drivers: [
      { title: 'Indication expansion waves', detail: 'New IO labels reopen sequencing debates hospital by hospital.' },
      { title: 'Biomarker capacity', detail: 'Testing turnaround gates eligible patient pools.' },
      { title: 'Antimicrobial stewardship', detail: 'ID and pharmacy policy shape anti-infective choice beyond price.' },
      { title: 'Regional budget variation', detail: 'Italy’s regionalisation creates uneven access timing.' },
      { title: 'Tender and net-price pressure', detail: 'Hospital purchasing compresses margins after list access.' },
      { title: 'Combination regimens', detail: 'Partner-drug access can stall or unlock protocol share.' },
    ],
  },
  marketStructure: {
    heading: 'Structure',
    paragraphs: [
      'Oncology IO and hospital anti-infectives share high-cost scrutiny but different clinical governors — oncology networks versus stewardship committees. BioNixus scopes modules by class and decides whether national, regional, or account-level cells are needed.',
    ],
  },
  audiences: [
    { audience: 'Medical oncologists', description: 'IO sequencing and protocol decision owners.' },
    { audience: 'Infectious disease & stewardship leads', description: 'Anti-infective policy gatekeepers.' },
    { audience: 'Hospital pharmacists', description: 'Formulary and tender influencers.' },
    { audience: 'Access / HEOR teams', description: 'AIFA and regional dossier owners.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/mek-inhibitors-market', label: 'MEK inhibitors market access' },
    { to: '/doxorubicin-market', label: 'Doxorubicin market access' },
    { to: '/febrile-neutropenia-market', label: 'Febrile neutropenia market' },
    { to: '/pharmaceutical-market-research-italy', label: 'Pharmaceutical market research Italy' },
    { to: '/healthcare-market-research/therapy/oncology', label: 'Oncology market research' },
    { to: '/italy-clinical-trials-market', label: 'Italy clinical trials market' },
  ],
  faqs: [
    {
      question: 'How does BioNixus research Italy Keytruda-class or daptomycin-class markets?',
      answer:
        'We run primary interviews with the clinical and formulary stakeholders who control protocol and funding decisions for the relevant class — IO oncology networks for checkpoint analogues; infectious-disease and hospital pharmacy for high-value anti-infectives — mapped to AIFA and regional access context.',
    },
  ],
  areaServed: ['Italy'],
  priority: 'later',
};

const gccFspMarket: SpecialtyMarketDemandContent = {
  slug: 'gcc-functional-service-providers-market',
  segmentLabel: 'GCC Functional Service Providers',
  badge: 'GCC · Clinical Development / FSP',
  breadcrumbLabel: 'GCC FSP Market',
  title: 'GCC Functional Service Providers (FSP) Market Research | BioNixus',
  description:
    'GCC functional service providers market research — FSP vs full-service outsourcing, clinical operations capacity, sponsor buyer criteria, and Gulf trial.',
  canonical: `${BASE}/gcc-functional-service-providers-market`,
  h1: 'GCC Functional Service Providers (FSP) Market: Sponsor & Delivery Intelligence',
  intro: [
    'The GCC functional service providers market sits at the intersection of rising Gulf clinical-trial ambition and sponsor preference for modular FSP models over full-service CROs. BioNixus researches sponsor clinical-operations leaders, site networks, and in-region delivery partners to show which FSP capabilities win Gulf assignments — monitoring, data management, medical writing, pharmacovigilance — and where full-service still dominates.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'Sponsor outsourcing model research', detail: 'When Gulf programmes choose FSP vs full-service vs hybrid.' },
    { name: 'Capability-by-function mapping', detail: 'Monitoring, DM, medical writing, PV, and biostat preferences.' },
    { name: 'In-region delivery diligence', detail: 'Arabic capability, hospital access, and travel logistics as win themes.' },
    { name: 'Site & investigator experience research', detail: 'How FSP CRA models feel to Gulf sites versus legacy CROs.' },
    { name: 'Pricing and governance interviews', detail: 'What KPIs and governance sponsors demand from FSP partners.' },
    { name: 'Competitive landscape briefs', detail: 'Global FSP brands vs regional specialists in Saudi Arabia and UAE.' },
  ],
  demandDrivers: {
    heading: 'Demand drivers',
    drivers: [
      { title: 'Gulf trial volume growth', detail: 'More Phase II–IV and RWE programmes need flexible resourcing.' },
      { title: 'Sponsor cost pressure', detail: 'FSP models promise utilisation control versus full-service lock-in.' },
      { title: 'Localisation expectations', detail: 'Saudi and UAE programmes favour partners with in-market presence.' },
      { title: 'Startup timeline scrutiny', detail: 'Site activation speed is a decisive selection criterion.' },
      { title: 'Therapeutic specialisation', detail: 'Oncology and rare-disease depth beats generic capacity claims.' },
      { title: 'Quality / inspection readiness', detail: 'GCP inspection risk pushes sponsors toward proven oversight models.' },
    ],
  },
  marketStructure: {
    heading: 'Structure',
    paragraphs: [
      'FSP buying in the GCC is rarely a single RFP for “the region.” Sponsors often lock global FSP frameworks then stress-test Middle East delivery cells. BioNixus scopes research to the function and geography under evaluation.',
    ],
  },
  signalGrid: {
    heading: 'Country signals',
    items: [
      { label: 'Saudi Arabia', signal: 'Largest trial and RWE ambition; localisation and SFDA context matter in partner choice.' },
      { label: 'United Arab Emirates', signal: 'Hub for regional PM and monitoring models with strong private hospital sites.' },
      { label: 'Qatar / Kuwait / Oman / Bahrain', signal: 'Smaller but strategically used cells — capacity realism is the diligence issue.' },
      { label: 'Egypt adjacency', signal: 'Often bundled into MENA FSP conversations for enrolment scale.' },
    ],
  },
  audiences: [
    { audience: 'Sponsor clinical operations', description: 'Outsourcing-model and vendor decision owners.' },
    { audience: 'FSP / CRO commercial leaders', description: 'Competitors and partners seeking Gulf win themes.' },
    { audience: 'Site / SMO leadership', description: 'Stakeholders who experience delivery quality day to day.' },
    { audience: 'Medical / PV oversight', description: 'Quality and compliance governors of modular models.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/gcc-clinical-trials-market', label: 'GCC clinical trials market' },
    { to: '/mea-clinical-trial-imaging-market', label: 'MEA clinical trial imaging market' },
    { to: '/healthcare-market-research', label: 'Healthcare market research hub' },
    { to: '/gcc-market-access-guide', label: 'GCC pharmaceutical market access guide' },
    { to: '/italy-clinical-trials-market', label: 'Italy clinical trials market' },
    { to: '/real-world-evidence', label: 'Real world evidence' },
  ],
  faqs: [
    {
      question: 'What is the GCC functional service providers market?',
      answer:
        'The market for modular clinical-development services (monitoring, data management, medical writing, PV, and related functions) sold into Gulf-sponsored or Gulf-executed programmes — researched through sponsor, site, and delivery-partner stakeholders.',
    },
  ],
  areaServed: ['Saudi Arabia', 'United Arab Emirates', 'Kuwait', 'Qatar', 'Oman', 'Bahrain'],
  priority: 'later',
};

const gccMedicationManagement: SpecialtyMarketDemandContent = {
  slug: 'gcc-medication-management-market',
  segmentLabel: 'GCC Medication Management',
  badge: 'GCC · Medication Management',
  breadcrumbLabel: 'GCC Medication Management Market',
  title: 'GCC Medication Management Market Research 2026 | BioNixus',
  description:
    'GCC medication management market: pharmacy automation, e-prescribing, Wasfaty workflows, and adherence programmes. Primary Gulf fieldwork. 48h proposal.',
  canonical: `${BASE}/gcc-medication-management-market`,
  h1: 'GCC Medication Management Market: Pharmacy, Automation & Adherence Intelligence',
  dateModified: '2026-11-04',
  geoAnswer:
    'The GCC medication management market spans hospital pharmacy automation, closed-loop e-prescribing, and adherence programmes — BioNixus interviews chief pharmacists, CIOs, and payer stakeholders to show which Gulf buyers fund automation versus software.',
  intro: [
    'The GCC medication management market covers hospital pharmacy automation, e-prescribing and closed-loop medication systems, and adherence / patient-support programmes that sit between IT, pharmacy, and clinical care. BioNixus researches chief pharmacists, hospital CIOs, and ambulatory stakeholders so vendors know which Gulf buyers fund automation versus adherence software — and what evidence they demand.',
    'Search interest in the GCC medication management market reflects hospital digitalisation and medication-error reduction agendas — not retail pharmacy alone. Saudi Wasfaty-linked ambulatory flows and UAE private hospital groups often lead adoption curves that later diffuse to other Gulf states.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  earlyLinks: [
    { to: '/healthcare-market-research/saudi-arabia', label: 'healthcare market research Saudi Arabia' },
    { to: '/gcc-pharmacy-market', label: 'GCC pharmacy market' },
  ],
  decisionBlueprint: {
    why: 'Medication management purchases fail when IT, pharmacy, and quality cannot align on integration and error-reduction proof — capital committees defer without a coalition sponsor.',
    evidence:
      'Chief pharmacist and CIO interviews show which closed-loop, ADC, and adherence claims survive diligence in Saudi, UAE, and smaller Gulf networks.',
    next: 'Pick decision cell (inpatient automation, e-Rx, or adherence), map country priorities, then run feasibility before multi-country roll-up.',
  },
  proofMetrics: [
    { label: 'Three-lane buy', detail: 'Pharmacy operations, IT integration, and patient safety quality each hold veto power.' },
    { label: 'Capital vs SaaS routes', detail: 'ADC and automation move on capex cycles; adherence software on payer or employer budgets.' },
  ],
  deliveryPriorities: [
    'Country-scoped modules (KSA, UAE, Kuwait/Qatar) with harmonised readout optional.',
    'Wasfaty / ambulatory linkage when Saudi outpatient programmes are in scope.',
    'Tender and mega-project calendar alignment for greenfield hospitals.',
  ],
  researchTopics: [
    {
      name: 'Hospital pharmacy automation research',
      detail: 'ADC, unit-dose, and compounding workflow adoption barriers by country and account tier.',
    },
    {
      name: 'E-prescribing / closed-loop meds',
      detail: 'HIS integration, clinician workflow friction, and cybersecurity review cycles.',
    },
    {
      name: 'Wasfaty and retail pharmacy linkage',
      detail: 'Saudi ambulatory medication management dynamics and prescriber behaviour.',
    },
    {
      name: 'Adherence programme effectiveness',
      detail: 'What employers, payers, and hospitals will sponsor for chronic therapies.',
    },
    {
      name: 'Procurement and tender mapping',
      detail: 'Capital vs SaaS buying routes across Gulf public and private hospitals.',
    },
    {
      name: 'Safety and shortage-use cases',
      detail: 'Error-reduction and inventory claims that survive quality and pharmacy diligence.',
    },
  ],
  demandDrivers: {
    heading: 'GCC medication management demand drivers',
    drivers: [
      { title: 'Hospital mega-projects', detail: 'New facilities prefer modern pharmacy workflows from day one.' },
      { title: 'Medication-error reduction targets', detail: 'Quality agendas fund closed-loop initiatives when IT agrees.' },
      { title: 'Pharmacy workforce pressure', detail: 'Automation pitched as staffing leverage faces culture filters.' },
      { title: 'Chronic disease burden', detail: 'Adherence and refill management rise on payer agendas.' },
      { title: 'National e-health programmes', detail: 'Integration standards shape vendor shortlists.' },
      { title: 'High-cost specialty drugs', detail: 'Inventory and cold-chain visibility become tender criteria.' },
    ],
  },
  marketStructure: {
    heading: 'GCC medication management market structure',
    paragraphs: [
      'Medication management sits across capital pharmacy automation and software/adherence layers. BioNixus scopes the decision cell first — inpatient automation, ambulatory e-Rx, or adherence — before fieldwork.',
      'Saudi MOH scale and UAE private groups create different adoption speeds — harmonised surveys still need country-specific qual cells.',
      'Tenders and mega-project RFPs bundle automation with HIS upgrades — vendors must map coalition buyers, not only pharmacy directors.',
    ],
  },
  methodologyParagraphs: [
    'Arabic–English moderation is standard for Gulf pharmacy and IT stakeholders. Feasibility documents hospital access and role validation before quant scales.',
  ],
  signalGrid: {
    heading: 'Country signals',
    items: [
      { label: 'Saudi Arabia', signal: 'Wasfaty, Vision 2030 hospitals, and large MOH networks drive ambulatory and inpatient programmes.' },
      { label: 'United Arab Emirates', signal: 'Private hospital groups and insurance pressures accelerate closed-loop and adherence pilots.' },
      { label: 'Kuwait / Qatar', signal: 'Compact hospital systems can standardise quickly when leadership sponsors change.' },
      { label: 'Oman / Bahrain', signal: 'Selective modernisation projects; localisation and service support weigh heavily.' },
    ],
  },
  audiences: [
    { audience: 'Chief pharmacists', description: 'Clinical and operational owners of medication systems.' },
    { audience: 'Hospital CIO / IT', description: 'Integration and cybersecurity gatekeepers.' },
    { audience: 'Quality / patient-safety leads', description: 'Error-reduction business-case sponsors.' },
    { audience: 'Payers & ambulatory programmes', description: 'Adherence and chronic-care funding stakeholders.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/gcc-pharmacy-market', label: 'GCC pharmacy market' },
    { to: '/gcc-generic-pharmaceuticals-market', label: 'GCC generic pharmaceuticals market' },
    { to: '/gcc-functional-service-providers-market', label: 'GCC FSP market' },
    { to: '/healthcare-market-research/saudi-arabia', label: 'Healthcare market research Saudi Arabia' },
    { to: '/blog/nupco-saudi-arabia-tendering-guide', label: 'NUPCO tendering guide' },
    { to: '/healthcare-market-research', label: 'Healthcare market research hub' },
  ],
  faqs: [
    {
      question: 'What is included in the GCC medication management market?',
      answer:
        'Hospital pharmacy automation, e-prescribing and closed-loop medication systems, inventory visibility, and adherence / patient-support programmes — researched through pharmacy, IT, and clinical stakeholders across Gulf markets.',
    },
    {
      question: 'What is the GCC medication management market?',
      answer:
        'The Gulf market for systems and programmes that manage prescribing, dispensing, administration, and adherence — spanning inpatient automation, ambulatory e-health, and chronic-care support.',
    },
    {
      question: 'How does BioNixus research GCC medication management?',
      answer:
        'Primary interviews with verified chief pharmacists, CIOs, quality leaders, and payer stakeholders — scoped to one decision cell and country set before field scales.',
    },
  ],
  areaServed: ['Saudi Arabia', 'United Arab Emirates', 'Kuwait', 'Qatar', 'Oman', 'Bahrain'],
  priority: 'later',
};

const doxorubicinMarket: SpecialtyMarketDemandContent = {
  slug: 'doxorubicin-market',
  segmentLabel: 'Doxorubicin Market Access',
  badge: 'Global / GCC · Oncology Access',
  breadcrumbLabel: 'Doxorubicin Market Access',
  title: 'Doxorubicin Market Access Research | BioNixus',
  description:
    'Doxorubicin market access research — liposomal vs conventional use, oncology protocols, hospital tender dynamics, and GCC supportive oncology intelligence.',
  canonical: `${BASE}/doxorubicin-market`,
  h1: 'Doxorubicin Market Access: Protocol, Tender & Formulation Intelligence',
  intro: [
    'The doxorubicin market is protocol- and tender-shaped: formulation choice (conventional vs liposomal), cardiotoxicity management, and hospital purchasing determine real utilisation more than awareness campaigns. BioNixus researches oncologists, oncology pharmacists, and tender stakeholders — including Gulf hospital settings — to map where brands and formulations win line placement.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'Protocol and line-of-therapy research', detail: 'Where doxorubicin remains foundational versus displaced by newer regimens.' },
    { name: 'Liposomal vs conventional preference', detail: 'Cardiotoxicity, convenience, and access barriers by formulation.' },
    { name: 'Hospital formulary / tender modules', detail: 'Award criteria and substitution behaviour for oncology injectables.' },
    { name: 'Supportive-care adjacency', detail: 'How FN and cardioprotection practice interact with doxorubicin use.' },
    { name: 'Competitive analogue libraries', detail: 'Messaging themes that defend or erode share.' },
    { name: 'GCC framework cycles', detail: 'NUPCO and hospital pull-through for listed oncology injectables.' },
  ],
  demandDrivers: {
    heading: 'Demand drivers',
    drivers: [
      { title: 'Enduring protocol roles', detail: 'Breast, sarcoma, and lymphoma regimens keep baseline demand.' },
      { title: 'Formulation competition', detail: 'Liposomal products compete on safety and access, not only price.' },
      { title: 'Tender and biosimilar pressure', detail: 'Hospital pharmacies switch aggressively after awards.' },
      { title: 'Cardiotoxicity stewardship', detail: 'Monitoring capacity and guidelines reshape regimen choice.' },
      { title: 'Combination innovation', detail: 'Partner regimens can expand or shrink doxorubicin exposure.' },
      { title: 'Supply reliability', detail: 'Shortage history influences dual-source policies.' },
    ],
  },
  marketStructure: {
    heading: 'Structure',
    paragraphs: [
      'Doxorubicin utilisation is oncology-network and hospital-pharmacy governed. BioNixus scopes by indication cluster and geography, and separates clinical preference from tender economics.',
    ],
  },
  audiences: [
    { audience: 'Medical oncologists', description: 'Protocol decision owners.' },
    { audience: 'Oncology pharmacists', description: 'Formulary and substitution influencers.' },
    { audience: 'Cardiology / cardio-oncology', description: 'Safety pathway stakeholders.' },
    { audience: 'Procurement / tenders', description: 'Framework and award decision makers.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/febrile-neutropenia-market', label: 'Febrile neutropenia market' },
    { to: '/mek-inhibitors-market', label: 'MEK inhibitors market access' },
    { to: '/italy-oncology-antiinfective-market-access', label: 'Italy oncology & anti-infective market access' },
    { to: '/gcc-generic-injectables-market', label: 'GCC generic injectables market' },
    { to: '/healthcare-market-research/therapy/oncology', label: 'Oncology market research' },
    { to: '/market-reports/gcc-oncology-market-report', label: 'GCC oncology market report' },
  ],
  faqs: [
    {
      question: 'What does doxorubicin market access research include?',
      answer:
        'Primary research with oncology and pharmacy stakeholders on formulation choice, protocol placement, cardiotoxicity practice, and hospital tender/substitution dynamics that govern real utilisation.',
    },
  ],
  priority: 'later',
};

const meaClinicalTrialImaging: SpecialtyMarketDemandContent = {
  slug: 'mea-clinical-trial-imaging-market',
  segmentLabel: 'MEA Clinical Trial Imaging',
  badge: 'Middle East & Africa · Clinical Trial Imaging',
  breadcrumbLabel: 'MEA Clinical Trial Imaging Market',
  title: 'Middle East & Africa Clinical Trial Imaging Market | BioNixus',
  description:
    'Middle East and Africa clinical trial imaging market research — central reads, site imaging capability, oncology and CNS endpoints, and sponsor/CRO buyer.',
  canonical: `${BASE}/mea-clinical-trial-imaging-market`,
  h1: 'Middle East & Africa Clinical Trial Imaging Market Intelligence',
  intro: [
    'The Middle East and Africa clinical trial imaging market is defined by site scanner readiness, central-read vendor selection, and protocol endpoint complexity — not radiology equipment sales alone. BioNixus researches sponsors, CROs, imaging core labs, and high-enrolment sites across GCC and selected African hubs to show where imaging capability unlocks country inclusion versus where it becomes a startup bottleneck.',
  ],
  hubLink: { to: '/healthcare-market-research', label: 'healthcare market research hub' },
  researchTopics: [
    { name: 'Site imaging capability audits', detail: 'Modality availability, technician training, and de-identification workflows.' },
    { name: 'Central-read vendor research', detail: 'Sponsor criteria for MEA-capable imaging core labs.' },
    { name: 'Oncology / CNS endpoint feasibility', detail: 'RECIST and specialised reads that strain regional capacity.' },
    { name: 'Startup timeline mapping', detail: 'Where imaging qualification delays country activation.' },
    { name: 'Data transfer & privacy diligence', detail: 'Cross-border imaging data handling expectations.' },
    { name: 'CRO / FSP interface research', detail: 'How imaging vendors fit modular Gulf and Africa delivery models.' },
  ],
  demandDrivers: {
    heading: 'Demand drivers',
    drivers: [
      { title: 'Gulf trial expansion', detail: 'More oncology and specialty trials need reliable imaging chains.' },
      { title: 'Endpoint complexity', detail: 'Advanced reads raise the bar for site qualification.' },
      { title: 'Centralisation of reads', detail: 'Sponsors prefer fewer core labs with MEA logistics proven.' },
      { title: 'Africa enrolment strategies', detail: 'Imaging readiness becomes a binding feasibility constraint.' },
      { title: 'Regulatory scrutiny', detail: 'Inspection readiness extends to imaging SOPs and archives.' },
      { title: 'Hybrid trial designs', detail: 'Decentralised elements still depend on quality imaging sites.' },
    ],
  },
  marketStructure: {
    heading: 'Structure',
    paragraphs: [
      'Clinical trial imaging in MEA is a services market layered on hospital radiology capacity. BioNixus separates site feasibility from central-read vendor selection so sponsors do not confuse equipment presence with trial readiness.',
    ],
  },
  signalGrid: {
    heading: 'Regional signals',
    items: [
      { label: 'GCC hubs', signal: 'Strongest scanner density and growing oncology trial mix; qualification still uneven by hospital.' },
      { label: 'Egypt / North Africa', signal: 'Enrolment scale with variable imaging SOP maturity across centres.' },
      { label: 'Sub-Saharan selected hubs', signal: 'Strategic sites for specific programmes; imaging often the critical path.' },
      { label: 'Central-read vendors', signal: 'Global vs regional capability claims require primary validation with sites.' },
    ],
  },
  audiences: [
    { audience: 'Sponsor imaging / clinical ops', description: 'Vendor and country-feasibility decision owners.' },
    { audience: 'CRO imaging leads', description: 'Delivery partners balancing site load and central reads.' },
    { audience: 'Site radiology / PI teams', description: 'Operational owners of scan quality and timelines.' },
    { audience: 'Imaging core labs', description: 'Competitors seeking MEA expansion intelligence.' },
  ],
  whyBionixus: SHARED_WHY,
  relatedLinks: [
    { to: '/gcc-clinical-trials-market', label: 'GCC clinical trials market' },
    { to: '/gcc-functional-service-providers-market', label: 'GCC FSP market' },
    { to: '/italy-clinical-trials-market', label: 'Italy clinical trials market' },
    { to: '/healthcare-market-research', label: 'Healthcare market research hub' },
    { to: '/real-world-evidence', label: 'Real world evidence' },
    { to: '/gcc-pharma-market-report-2026', label: 'GCC pharmaceutical market report 2026' },
  ],
  faqs: [
    {
      question: 'What is the Middle East and Africa clinical trial imaging market?',
      answer:
        'The services and capability ecosystem for qualifying trial sites, transferring imaging data, and delivering central reads for protocols run in GCC, North Africa, and selected Sub-Saharan hubs — researched through sponsors, CROs, core labs, and sites.',
    },
  ],
  priority: 'later',
};

function withLongFormSections(pages: SpecialtyMarketDemandContent[]): SpecialtyMarketDemandContent[] {
  return pages.map((page) => {
    const longFormSections = SPECIALTY_DEMAND_LONG_FORM[page.slug];
    const extraFaqs = SPECIALTY_DEMAND_EXTRA_FAQS[page.slug];
    const faqs = [...page.faqs, ...(extraFaqs ?? [])];
    if (longFormSections) {
      faqs.push({
        question: `How do I request ${page.segmentLabel} research from BioNixus?`,
        answer:
          `Use the research proposal contact form with your decision date, target accounts, and countries. BioNixus replies within forty-eight hours with feasibility, stakeholder mix, and scoped pricing — primary modules typically start at USD 20,000 depending on incidence and qual depth. Syndicated audits rarely answer ${page.segmentLabel.toLowerCase()} committee questions; our field is built for medical affairs, access, and commercial decisions that require verified hospital, lab, or oncology stakeholders.`,
      });
      faqs.push({
        question: `Does BioNixus sell syndicated ${page.segmentLabel.toLowerCase()} market reports?`,
        answer:
          `No — this page describes primary research programmes, not syndicated PDFs. Sponsors commission scoped interviews and surveys when they need stakeholder-specific barriers, tender calendars, or protocol behaviour that secondary data cannot supply. Deliverables are decision memos, objection libraries, and action plans your teams can defend in committee.`,
      });
    }
    const merged: SpecialtyMarketDemandContent = {
      ...page,
      ...(longFormSections ? { longFormSections } : {}),
      faqs,
    };
    return merged;
  });
}

export const SPECIALTY_MARKET_DEMAND_CONTENT: SpecialtyMarketDemandContent[] = withLongFormSections([
  singaporeMedtechManufacturing,
  singaporePharmaceuticalMarket,
  japanGeneralSurgicalDevices,
  healthcareBioconvergence,
  nupcoTenderCalendar,
  singaporeIvdMarketAccess,
  japanNeurologyDevices,
  japanMedicalDisposables,
  japanMedtechAccessAutomation,
  italyClinicalTrials,
  mekInhibitors,
  febrileNeutropenia,
  italyPortableDiagnostics,
  italyDeviceConnectivity,
  italyOncologyAntiInfectiveAccess,
  gccFspMarket,
  gccMedicationManagement,
  doxorubicinMarket,
  meaClinicalTrialImaging,
]);

export const SPECIALTY_MARKET_DEMAND_BY_SLUG: Record<string, SpecialtyMarketDemandContent> =
  Object.fromEntries(SPECIALTY_MARKET_DEMAND_CONTENT.map((item) => [item.slug, item]));

export function getSpecialtyMarketDemandSitemapEntries(): Array<{
  path: string;
  priority: string;
  changefreq: string;
}> {
  return SPECIALTY_MARKET_DEMAND_CONTENT.map((item) => ({
    path: `/${item.slug}`,
    priority: item.priority === 'now' ? '0.90' : item.priority === 'next' ? '0.86' : '0.84',
    changefreq: 'monthly',
  }));
}
